2015

PHARMACOLOGIC INDUCTION OF THE MELANOCOTIN 1 RECEPTOR (MC1R) PATHWAY PROVIDES PROTECTION AGAINST SUNBURN AND ENHANCES EXPRESSION OF ANTIOXIDANT ENZYMES IN THE SKIN

Alexandra Amaro-Ortiz
University of Kentucky, aalma2@uky.edu

Click here to let us know how access to this document benefits you.

Recommended Citation
Amaro-Ortiz, Alexandra, "PHARMACOLOGIC INDUCTION OF THE MELANOCOTIN 1 RECEPTOR (MC1R) PATHWAY PROVIDES PROTECTION AGAINST SUNBURN AND ENHANCES EXPRESSION OF ANTIOXIDANT ENZYMES IN THE SKIN" (2015). Theses and Dissertations--Toxicology and Cancer Biology. 9.
https://uknowledge.uky.edu/toxicology_etds/9

This Doctoral Dissertation is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Toxicology and Cancer Biology by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
STUDENT AGREEMENT:

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File.

I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

REVIEW, APPROVAL AND ACCEPTANCE

The document mentioned above has been reviewed and accepted by the student’s advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student’s thesis including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Alexandra Amaro-Ortiz, Student

Dr. John A. D’Orazio, Major Professor

Dr. Liya Gu, Director of Graduate Studies
PHARMACOLOGIC INDUCTION OF THE MELANOCOTIN 1 RECEPTOR (MC1R) PATHWAY PROVIDES PROTECTION AGAINST SUNBURN AND ENHANCES EXPRESSION OF ANTIOXIDANT ENZYMES IN THE SKIN.

DISSERTATION

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the College of Medicine at the University of Kentucky

By
Alexandra Amaro-Ortiz
Lexington, Kentucky

Director: John A. D’Orazio
Lexington, Kentucky
2015

Copyright © Alexandra Amaro-Ortiz 2015
ABSTRACT OF DISSERTATION

PHARMACOLOGIC INDUCTION OF THE MELANOCORTIN 1 RECEPTOR (MC1R) PATHWAY PROVIDES PROTECTION AGAINST SUNBURN AND ENHANCES EXPRESSION OF ANTIOXIDANT ENZYMES IN THE SKIN.

The inability to tan properly after sun exposure strongly correlates with increased incidence of skin cancer. The melanocortin 1 receptor (MC1R) is a transmembrane Gs-coupled cell surface receptor found on epidermal melanocytes that transmits pro-survival and pro-differentiation signals mediated by the second messenger cAMP. Humans carrying loss-of-function polymorphisms in MC1R signaling exhibit higher incidences of skin cancers including melanoma.

This study focused on the physiologic effects of topical application of forskolin, an adenylate cyclase activator, in extension (Mc1re<sup>+/−</sup>) K14-SCF animals, which model the fair-skinned UV-sensitive human. Twice daily application of the drug promoted accelerated pigmentation, increased skin darkening due to epidermal deposition of melanin pigment, and induced epidermal melanin, which protected the skin against UV injury as judged by “minimal erythematous dose” (MED). Moreover, MC1R signaling regulated the expression of antioxidant enzymes at the transcriptional level. The human melanoma cell line A375, known to harbor a loss-of-function signaling mutation in MC1R, was used to determine effects of cAMP stimulation on the expression of antioxidant enzymes. We observed increases in expression of genes that control the biosynthesis and regulation of glutathione including the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), glutathione peroxidase, GPX, and glutathione reductase GSR. In addition, there is an increase in manganese superoxide dismutase (MnSOD) at the protein level. There was accumulation of MnSOD in the mitochondria after pharmacologic induction of cAMP with forskolin. Addition of the oxidative agent H<sub>2</sub>O<sub>2</sub> enhanced the expression of MnSOD at the protein level as early as one hour after MC1R stimulation. Oxygen consumption rate on mitochondria was measured using Seahorse analysis; pharmacologic activation of MC1R/cAMP signaling did not affect mitochondrial metabolism. In addition, topical application of a crude extract of <i>Solidago</i> inhibited UV-induced inflammation in <i>K14-SCF</i> mice. Several UV-induced cytokines, including TNF-α, were down-regulated at the transcriptional level after topical application of Solidago extract.

Together, these results indicate that MC1R signaling protects melanocytes from UV damage by regulating antioxidant enzyme expression and suggest that pharmacologic cAMP induction may be a useful preventive mechanism against UV-mediated skin sunburn and oxidative injury.
KEYWORDS: UV, skin cancer, melanocortin 1 receptor (Mc1r), forskolin, cAMP.
PHARMACOLOGIC INDUCTION OF THE MELANOCORTIN 1 RECEPTOR (MC1R) PATHWAY PROVIDES PROTECTION AGAINST SUNBURN AND ENHANCES EXPRESSION OF ANTIOXIDANT ENZYMES IN THE SKIN.

By
Alexandra Amaro-Ortiz

John A. D’Orazio
Director of Dissertation

Liya Gu
Director of Graduate Studies

Date
Dedicated to my family and God
ACKNOWLEDGMENTS

The following dissertation, while an individual work, benefited from the insights and direction of several people. I want to express my appreciation to my dissertation chair Dr. John A. D’Orazio for giving my instructive guidance and for his invaluable patience. This project would not have been possible without his encouragement during all these years while maintaining a healthy work environment. I want to thank my Dissertation Committee, Dr. D. Allan Butterfield, Dr. Xianglin Shi and Dr. Daret St. Clair for agreeing to help me during the development of this project, challenging my critical thinking and improving my ideas and experiments. I am also grateful to Dr. Hollie Swanson for agreeing to be my outside examiner.

Next I want to thank the current and past members of the laboratory: Dr. Stuart Jarrett, Erin Wolf Horrell, Dr. Patience Murapa, Dr. Perry Christian, Dr. Tim Scott, Jason Tucker, and Jillian Vanover. All of them were available to provide their support and technical assistance. My special thanks to Carol Beach, Greg Bauman, Jennifer Strange and Mihail Mitov from the Proteomics Core facility, the Flow Cytometry and Cell Sorting and the Free Radical Biology in Cancer shared resource facilities for their guidance in the experimental design. Many thanks to the Research Communication Office at the Markey Cancer Center, the Robert E. Hemenway Writing Center and the Graduate School. I would like to thank Dr. Mary Vore, past and current students together with the administration personnel at the Department of Toxicology and Cancer Biology (former Graduate Center of Toxicology) for encouraging students to pursue a career in science by completing a Ph. D. degree in a supportive environment.

I am grateful for the financial support of the Lyman T. Johnson Pre-doctoral Fellowship and the National Cancer Institute during my research training.

I am very thankful to my friends Dr. Janice Ortega, Dr. Enerlyn Lozada, Dr. Joanne Collazo, Dr. Maria del Mar Landrón, Rev. Héctor Rodríguez, Adelka, Wilnery, Roselyn and Carmen. “Friends are the family that you choose.” It is a privilege to be part of this family of Puerto Ricans that are always available and I can count on at all times. Thank you for your loving support at frustrating times.

Most importantly, I want to thank my family in Puerto Rico: my dad Francisco, my mom Fanny, Noelia, Yelitza, Lorenzo, Mikaela, Amanda and my 100 year old grandmother Balbina. I have the privilege of being loved by all these people while been away. Their support is invaluable; I love them all and I thank them for their patience during all these years.

Lastly I want to thank God. Faith and hope are very important throughout all decisions in my life. I believe that God is always available to me, making a different in all my success. There were some difficult times but here I am presenting my final work. It is my duty and salvation to give you thanks always and everywhere almighty God.
# TABLE OF CONTENT

Acknowledgments ........................................................................................................................ iii
List of Tables .................................................................................................................................. vii
List of Figures ............................................................................................................................... viii
Chapter 1 ........................................................................................................................................ 1
  Introduction ................................................................................................................................. 1
    The skin .................................................................................................................................. 1
    Ultraviolet (uv) and Solar radiation ....................................................................................... 4
    Melanin ................................................................................................................................... 9
    Skin cancer ............................................................................................................................... 12
    Oxidative injury ...................................................................................................................... 16
    Antioxidant enzyme expression ............................................................................................. 18
    Melanocortin 1 receptor (MC1R) .......................................................................................... 22
    K14-SCF Transgenic mouse model ......................................................................................... 27
    Forskolin ................................................................................................................................. 28
    Forskolin-mediated melanin rescue ....................................................................................... 31
    Melanin-independent effects ................................................................................................. 32
    Rationale ................................................................................................................................. 33
    Project objectives ..................................................................................................................... 34
Chapter 2 ...................................................................................................................................... 35
  Introduction ............................................................................................................................... 35
    SPECIFIC AIM: ...................................................................................................................... 37
  Methods and Materials ............................................................................................................... 37
    Mouse colony ........................................................................................................................... 37
    Reagents and materials .......................................................................................................... 37
    Preparation of forskolin extract for topical administration was from a crude root of the Plectranthus barbatus (Coleus Forskohlii) plant .................................................. 38
    Preparation of C57Bl/6 K14-SCF mice for topical treatments .................................................. 38
  Statistical analysis ...................................................................................................................... 39
Results .......................................................................................................................................... 39
  Forskolin-induced melanization of fair-skinned mice ................................................................. 39
  Topical forskolin decreases UV sensitivity ................................................................................ 40
Discussion ................................................................................................................................ 44

Chapter 3 ...................................................................................................................................... 47
Introduction .................................................................................................................................... 47
  SPECIFIC AIM: ................................................................................................................................. 50

Methods and Materials .................................................................................................................. 50
  Cell lines and plasmids .................................................................................................................. 50
  Reagents ........................................................................................................................................ 51
  Isolation of primary melanocytes ................................................................................................. 51
  mRNA isolation from tissue samples .............................................................................................. 51
  qPCR .............................................................................................................................................. 52
  XL-PCR ........................................................................................................................................... 52
  Chloramphenicol resistance assay ................................................................................................. 53
  Western blot, Immuno-precipitation and Activity Assay ............................................................... 53
  Mitochondria isolation .................................................................................................................... 54
  Transfection FLAG-tagged MnSOD Plasmid ................................................................................. 55
  Protein Kinase assay ......................................................................................................................... 55
  Seahorse analysis ............................................................................................................................. 55
  Statistical analysis ............................................................................................................................ 56

Results ............................................................................................................................................ 56
  MC1R increases expression of antioxidant enzymes at the transcription level. .......................... 56
  MC1R increases MnSOD protein levels in mitochondria at early time points. ............................ 58
  MC1R signaling increases MnSOD interaction with chaperone protein HSP70. ....................... 58
  MnSOD interaction with HSP70 is PKA dependent ....................................................................... 59
  Forskolin rescue of MC1R signaling increases MnSOD activity ................................................. 60
  MC1R signaling does not affect mitochondria metabolism .......................................................... 60

Discussion ...................................................................................................................................... 72

Chapter 4 ...................................................................................................................................... 76
Summary ....................................................................................................................................... 76
  Future directions .............................................................................................................................. 78
  Conclusion ..................................................................................................................................... 81

Appendix A: .................................................................................................................................... 82
Goldenrod Extract decreases the anti-Inflammatory capacity of fair-skinned mice after UV-induced erythema in the skin ........................................................................................................ 82
  Introduction ...................................................................................................................................... 82
LIST OF TABLES
Table 3-1. Antioxidant enzymes gene array expression after forskolin treatment............64
LIST OF FIGURES
Figure 1-1. Schematic representation of epidermal differentiation. ......................... 3
Figure 1-2. UV exposure of the skin. ........................................................................ 5
Figure 1-3. The synthesis of melanin. ...................................................................... 10
Figure 1-4. The progression of skin cancer.................................................................14
Figure 1-5. Antioxidant enzymes and oxidative stress .................................................17
Figure 1-6. The signaling pathway of Nrf2 and NfκB after cell injury. .........................20
Figure 1-7. The adaptive tanning response.................................................................24
Figure 1-8. The structure of forskolin. ....................................................................29
Figure 2-1. Topical treatment of forskolin promotes skin darkening in fair-skinned extension. ..........................................................................................41
Figure 2-2. Twice daily application of Forskolin induces MC1R signaling. ..........42
Figure 2-3. Forskolin-induced melanization protected against UV-mediated inflammation as determined by minimal erythematous dose (MED) testing. .......................43
Figure 3-1. The level of mtDNA damage in melanoma cell lines. .........................49
Figure 3-2. MITF and SOD2 gene expression were rescued after forskolin treatment in whole skin tissue. ............................................................62
Figure 3-3. MITF gene expression was rescued after forskolin treatment. ..........63
Figure 3-4. MnSOD protein expression did not change after forskolin treatment in whole cell lysates but did increase in mitochondria..................................................65
Figure 3-5. MnSOD protein expression increased after forskolin treatment in mitochondria.................................................................................................66
Figure 3-6. The role of mutated and wild-type MC1R signaling role in the expression of MnSOD. .............................................................................................................67
Figure 3-7. HSP70 binds to MnSOD after MC1R activation .........................................68
Figure 3-8. FLAG-tagged MnSOD binding to HSP70 is PKA dependent....................69
Figure 3-9. MnSOD protein activity did not change after forskolin treatment. ..........70
Figure 3-10. MC1R signaling did not affect mitochondria metabolism.........................71
Figure 4-1 Schematic representation of the research project.......................................77
CHAPTER 1

INTRODUCTION

THE SKIN

The skin is the largest organ of the human body with an average area of 1.5 square meters and it consists of 16% of total body mass. The skin provides physical protection to the body from environmental, chemical and microbiologic treats. The skin thickness varies around the body with a range of 1.0 mm in the eyelids and 4 mm in the ball of the foot (Stucker, Struk et al. 2002). Epithelial, mesenchymal, granular, and neurovascular components come together to compose the skin. Once it is fully developed, there are two main layers: the epidermis and the dermis.

THE EPIDERMIS

The epidermis consists of mainly keratinocytes and it is the outmost layer of the skin. The epidermis can be as thin as 0.1 mm and it is characterized by several functional layers of differentiated keratinocytes (Fig. 1-1). The epidermis is a self-renewing tissue; there is constant division of keratinocyte stem cells in the stratum basale to move from the basal layer to form nascent epidermal keratinocytes. These cells accumulate keratin, melanin pigment and form tight junctions with each other. The outermost layer of the epidermis consists of terminal differentiated corneocytes that are dead, yet intact cells that are essential to create the protective physiochemical barrier of the epidermis through tight-linkages (Goodman, Miller et al. 2002).

MELANOCYTES

The skin is organized into “epidermal melanin units” wherein many keratinocytes interact with one melanocyte (Fig 1-1). Melanocytes are the second most common cell type in the epidermis (Barker, Dixon et al. 1995). Melanocytes are derived from neural crest cells that
have migratory characteristics together with peripheral and enteric neurons that migrate to specific locations during embryonic development. These cells are called melanoblast cells, which are un-pigmented and undifferentiated precursors of melanocytes that commit a dorsal-ventral migration to its final location in the body. Melanoblast differentiate to melanocytes once established in the basal layer of the epidermis. However, melanocytes are also found in the inner ear, the iris and behind the retina. Once located in the skin, melanocytes synthetize melanin in melanosomes. The melanosomes are vesicles responsible for the storage and transport of melanin to keratinocytes upon exposure to solar radiation. Keratinocytes receive melanin pigments from melanosomes (Easty, Patel et al. 1988, Lowings, Yavuzer et al. 1992) providing a barrier against accumulation of damaging levels UV radiation.

THE DERMIS
The dermis is located directly below the epidermis and it can be as thick as 2mm. The epidermis and the dermis are separated by a thin basement membrane. The dermis is a supportive layer of the skin with most dermal cells being derived from mesoderm. The most common feature of the dermis is the presence of hair follicles among other components of cutaneous structures including nerves, blood vessels, sebaceous glands and sweat glands. The presence of immune cells in the dermis contributes to the immune responses, and fibroblast cells participate in the formation of the extracellular matrix and collagen.
Figure 1-1. Schematic representation of epidermal differentiation.

The epidermal unit shows the presence of melanocytes at the basal membrane. The keratinocytes are located around the melanocytes and start to differentiate from the stratum basale. There are three differentiation stages stratum spinosum, granulosum and lucidum. Each layer is characterized by the induction and accumulation of different skin markers such as keratins, cornifin, filaggrin among others while the cells are differentiated to the surface. The corneum layer is composed of dead that serve as the outer layer of the skin.
ULTRAVIOLET (UV) AND SOLAR RADIATION

Due to its anatomic location at the external boundary of the body, the skin is exposed to a variety of environmental factors such as UV radiation that derives naturally from the sun. UV radiation is composed of UVA, UVB and UVC components based on photon wavelength. UVA has the longest wavelengths (315-400 nm), UVB mid-range in the spectrum (290-320 nm) and UVC has the shortest wavelengths (100-280 nm). Ambient sunlight exposure is composed primarily of UVA (90-95%) and UVB (5-10%) energy, with most solar UVC absorbed by the ozone layer (Fig. 1-2). UV radiation is an environmental factor that induces skin pathologies, including erythema (Wenczl, Pool et al. 1997, Amaro-Ortiz, Vanover et al. 2013, D’Orazio, Jarrett et al. 2013), inflammation (Rees 2004), aging effects (Dalziel 1991), sunburn (Autier and Dore 1998, Mallet, Kypriotou et al. 2013) and cancer. Unprotected exposure to solar radiation is very common and this leads to deleterious cutaneous effects.

UVA and UVB spectra penetrate the skin differently. Variations in skin thickness and the presence of melanin influence absorption of UV light. Epidermal melanin is able to transmit and reflect UV emissions of less than 300 nm (Anderson and Parrish 1981) which explains why UVA penetrates the skin more deeply than UVB despite UVA having a lower energy profile to UVB. Similarly to melanin, other molecules like urocanic acid and the amino acids tryptophan and tyrosine can absorb lower UV wavelength. On the other hand, the dermis seems to have more transmittance and reflectance for longer wavelength such as the one emitted by UVA. Dermal scattering is higher at lower wavelength allowing UVA-visible-infrared spectrum wavelengths to penetrate the dermis (Anderson and Parrish 1981). Other components of the dermis such as hemoglobin, bilirubin and beta-carotene are major absorbents of visible radiation compared to melanin in which the absorption of visible spectrum is negligible (Anderson and Parrish 1981, Parrish, Zaynoun et al. 1981).
Figure 1-2. UV exposure of the skin.

UV radiation in ambient sunlight is composed primarily of UVA and UVB energy. The ozone absorbs most UVC; therefore, although it is highly bioactive, terrestrial organisms are not exposed to significant levels of UVC. UVB can cause direct damage to DNA and reach the epidermis. UVA can penetrate the dermis and increases levels of ROS that indirectly induce DNA mutagenesis. The outcomes of both, UVA and UVB, in the skin are listed.

UVB is a well-characterized mutagen and inducer of skin cancers (Barker, Dixon et al. 1995, Darwiche, Bazzi et al. 2005, Ahsan, Reagan-Shaw et al. 2007, Grant 2008), but recent studies have implicated an increasing role for UVA as a carcinogen (Paunel, Dejam et al. 2005, Venditti, Bruge et al. 2011, Akhalaya, Maksimov et al. 2014) likely through its pro-oxidative effects and possibly through other mechanisms such as telomere shortening (Yin and Jiang 2013). In addition, UVA is less able to induce melanin production compared to UVB, leaving the skin less able to protect itself against further UV insult (Atillasoy, Seykora et al. 1998, Grant 2008, Wendt, Schanab et al. 2012, Flament, Bazin et al. 2013, Yin and Jiang 2013). Increasing attention is being paid to the potential impact of UVA radiation to areas of the body rarely exposed to natural UV, including the vulva and oral mucosa, even focusing on differential cellular repair and apoptosis depending on anatomic site (Breger, Baeva et al. 2013). Much of solar UV energy is absorbed by stratospheric ozone, and the gradual depletion of stratospheric ozone over the last several decades has resulted in higher levels of solar UV radiation that strikes the surface of the Earth (Norval, Lucas et al. 2011). Increased ambient UV radiation from global climate change may be an important factor to explain the increasing prevalence of melanoma and skin cancer over the last several decades (Armstrong and Kricker 2001, Diffey 2004, Garbe and Leiter 2009, Rigel, Russak et al. 2010). Both direct and indirect DNA changes interfere with transcription and replication, and render skin cells susceptible to mutagenesis. UV radiation induces a variety of free radical and oxidative molecules, which because of their chemical reactivity alter the molecular structure and damage lipids, proteins and nucleic acids (Chedekel and Zeise 1988).

UV-INDUCED DIRECT DNA DAMAGE

UV light has direct effects on DNA bases. The bases most susceptible to UV injury are pyrimidines. The rates of UV signature lesions include two third cyclobutane pyrimidine
dimers (CPD) and one third 6-4 pyrimidine photoproducts (6-4PP) caused by UV (Roza, van der Wulp et al. 1988, Estil, Olsen et al. 1997). CPD are formed when there is a base substitution of a cytosine → thymine at a di-pyrimidine site. On the other hand, 6-4PP are formed when two adjacent pyrimidines undergo photochemical reaction at the 6th and 4th position of the pyrimidine residues forming a novel 5-6 double bond with the exocyclic moiety of an adjacent 3' pyrimidine (Johns and Butler 1964, Sarasin 1999). The shift of the helical distortion in the backbone of DNA caused by 6-4PP blocks DNA replication. Both of these lesions distort the double helix and can lead to mutation. An individual skin cell may accumulate up to 100,000 such lesions from one day’s worth of sun exposure (Hoeijmakers 2009). These UV lesions if not repaired can lead mutagenesis. There are mechanisms of DNA repair available for the removal of these lesions.

MECHANISM OF DNA DAMAGE REPAIR

The nucleotide excision repair (NER) pathway is the main mechanism for the repair of CPD and 6-4PP. The NER pathway involves two types of repair, Transcription Coupled (TCR) and Global Genome Repair (GCR) (Gillet and Scharer 2006) that only differ in their damage recognition complex. Deficiency in any of the enzymes involved in NER leads to Xeroderma Pigmentosum (XP), a clinical condition characterized by chronic and excessive UV sensitivity. Many of the enzymes involved in this pathway have been named after this condition. TCR involves RNA polymerase which stalls at a lesion in the DNA template of actively transcribed genes. GGR is not dependent on transcription but senses damage by the XPC-HHR23B complex that recognizes distortions in the DNA helix. After damage is found, there is recruitment of other NER factors like XPE. XPA unwinds the DNA followed by RPA that stabilized the DNA for the recruitment of XPB and XPD. XPG and XPF promote excision of the damaged oligonucleotide and DNA polymerase promotes DNA synthesis with a DNA ligase finalizing the repair process.
The NER pathway may fail to repair UV-damage DNA. In those cases, the translesion DNA synthesis (TLS) pathway is the cellular mechanism (DNA damage tolerance) in response to DNA lesions caused during replication. This pathway includes three polymerases η, ζ and REV1 that repairs DNA in an error-free (mutation avoiding) or error-prone (mutation generating) mechanism (Goodman, Miller et al. 2002, Tsaalbi-Shtylik, Verspuy et al. 2009). During replication via an error-free mechanism, pol η uses the undamaged strand as a template to prevent mutation while REV1 creates a deletion by bypassing the damaged region during replication (Tsaalbi-Shtylik, Verspuy et al. 2009). Other types of UV lesions are found on C-phosphate-G (CpG) sites such as methylation of cytosine, 5mC (Ikehata, Kumagai et al. 2013). This mutation is common in the tumor suppressor gene p53 (van Kranen, de Gruijl et al. 1995, Cui, Widlund et al. 2007).

UV-INDUCED INDIRECT DNA DAMAGE

UV radiation also damages cellular macromolecules indirectly, through production of oxidative free radicals (Meyskens, Farmer et al. 2001). Several DNA modifications can result from oxidative injury, including 7, 8-dihydro-8-oxoguanine (8-OHdG), which promotes mutagenesis (specifically GC-TA transversion mutations) (Schulz, Mahler et al. 2000). UVA-induced ROS in the skin causes oxidation at the eighth position of guanine producing 8-OhdG (Nishimura 2002, Kunisada, Sakumi et al. 2005). This DNA product, if not repaired, will pair with an adenine instead of cytosine. Then, in the next step of replication, the adenine will pair with a thymine inducing a mutation. Cellular maintenance pathways exist to inactivate oxidative species as well as to repair the DNA damage these species may cause.

MECHANISM OF DNA DAMAGE REPAIR

The base excision repair pathway (BER) is the main molecular mechanism by which cells reverse free radical damage in DNA to avoid oxidative mutagenesis (Wyatt, Allan et al. 2002).
This pathway is initiated by lesion-specific glycosylases that scan DNA for specific alterations including deaminated, alkylated or oxidized bases. The glycosylase known to remove 8-OhdG is called 8-oxoguanine glycosylase, OGG. OGG has been studied as a key DNA repair enzyme after UV-induced DNA oxidation (Kadekaro, Chen et al. 2012). The glycosylase cleaves the N-glycosidic bond that connects the base to the sugar, creating an abasic site (AP site). The generation of the AP site recruits an AP endonuclease to hydrolyze the phosphodiester bond while the glycosylase cleave the 3’ AP-Site. The residues that are formed are processed by deoxyribose phosphodiesterase that removes the residual deoxyribose phosphate unit to facilitate DNA synthesis with a DNA polymerase and a DNA ligase seals the strand (Wyatt, Allan et al. 1999).

MELANIN

UV radiation can directly damage the skin. Melanin deposited in keratinocytes can efficiently block the penetration of UV radiation in the skin (Hollis and Scheibner 1988). A critical mediator of UV sensitivity and skin cancer risk is skin complexion, which is determined primary by the amount and type of melanin present in the epidermis. Melanin is derived from the amino acid tyrosine. Melanin is a large bio-aggregate of pigmented chemical species (Fig. 1-3). Tyrosine is converted through various steps to melanin (Jimbow, Alena et al. 1992, Fuller, Drake et al. 2000). Tyrosinase is the rate-limiting biosynthetic enzyme in the melanogenesis pathway, as it catalyzes the first two steps of melanin synthesis (conversion of tyrosine to DOPA and then to DOPAquinone). There are two major “mature” forms of melanin known as eumelanin and pheomelanin (Wakamatsu, Kavanagh et al. 2006, Ito and Wakamatsu 2011). The synthesis of melanin occurs by successive oxidation and cyclization steps (Kim, Song et al. 2010, Kim 2014, Kim, Baek et al. 2015).
Figure 1-3. The synthesis of melanin.

There are two forms of melanin: dark/black eumelanin and light/red pheomelanin. Both eumelanin and pheumelanin are derived from the amino acid tyrosine. Tyrosinase catalyzes the rate limiting reaction from the synthesis of melanin. The incorporation of cysteine in the biosynthesis of melanin leads to the light/red color of pheomelanin. There are other enzymes that trigger the synthesis of dark/black eumelanin (Tyrp1, Tyrp2, tautomerase). The expression of mutated Tyrosinase has a phenotype of albinism.
Eumelanin protects against UV exposure by interfering with UV entry into the deeper, sensitive layers of the skin. Eumelanin is a dark brown/black pigment in contrast to pheomelanin, which is a light red pigment less able to block UV. Pheomelanin is a sulfur containing pigment that may actually potentiate UV injury in the skin. Pheomelanin contributes to free radical formation and oxidative cellular damage (Mitra, Luo et al. 2012).

In addition, the structure of pheomelanin is photosensitive and increases pro-oxidant levels in the skin (Salopek, Yamada et al. 1991). Therefore, individuals with high levels of pheomelanin and low levels of eumelanin in the skin are UV sensitive and are at a greater risk for developing skin cancers including melanoma (Wakamatsu, Kavanagh et al. 2006).

If the skin is continually stimulated for melanin production, the melanin will stay and deposit in keratinocytes until the UV exposure is removed. Dark pigmented skin is protected against formation of CPD (Yamaguchi, Coelho et al. 2008), photoproducts (de Lima-Bessa, Armelini et al. 2008), and a decrease in oxidative stress (Jenkins and Grossman 2013).

Various inherited and environmental factors control the ratio of eumelanin-to-pheomelanin in total amount of melanin. When melanocytic cytoplasmic cAMP levels are high, eumelanin production is favored compared to lower levels of cAMP that induce the synthesis of pheomelanin. Individuals can be categorized by phenotype of skin complexion using the Fitzpatrick Scale. This scale ranges from very fair skin (e.g. Northern Europeans type I) to very dark (e.g. for Aboriginal African type VI). Risk of sunburn is linked to not only UV dose and intensity of UV exposure, but also by hereditary factors that influence cutaneous response to UV radiation. Many factors determine melanocytic response to UV. Skin cancer risk is inversely proportional to phenotype scale in which a type 1 skin complexion has a higher risk than type VI.
SKIN CANCER

Skin cancer is the most diagnosed cancer in United States and it is caused by an uncontrolled growth of genetically mutated skin cells. There are keratinocyte and melanocyte malignancies that, together, are by far the most numerous cancers diagnosed today (Lo and Fisher 2014). Skin pigmentation is one of the most important determinants of UV sensitivity. Melanoma, the most deadly form of skin cancer, occurs roughly twenty times more frequently in light-skinned persons compared to their dark-skinned (Tucker 2009, Psaty, Scope et al. 2010, Udayakumar, Mahato et al. 2010). Because of low innate levels of eumelanin pigment in the epidermis, fair-skinned individuals are much more prone to acute and chronic effects of UV radiation including sunburns, photo-aging and skin cancers (Conley and Pack 1963, Evans, Kopf et al. 1988, Gibson, Donald et al. 1997). Besides innate skin pigmentation, the ability to tan after sun exposure is also another important determinant of UV sensitivity (Suzuki, Im et al. 1999, Abdel-Malek, Knittel et al. 2008, Munoz-Hidalgo, Lopez-Gines et al. 2014).

NON MELANOMA SKIN CANCER

Non-melanoma skin cancer (NMSC) develops from abnormal keratinocytes. These types of cancer include basal cell (BCC) or squamous cell carcinomas (SCC), which are generally diagnosed early and are treated surgically. Actinic keratosis (AK) was identified as an early stage of NMSC and if left untreated, up to ten percent of cases of AK can develop into SCC. There is an estimate increase of 200 percent in the diagnosis of SCC in USA since 1990. This type of cancer is generated in outer layers of the epidermis, starting in a localized area in the skin and caused by long-term exposure to solar radiation. BCC accounts for 80% of NMSC cases and almost never metastasizes (Gupta, Daigle et al. 2014). BCC is generated from deeper areas of the epidermis and has been characterized for its slow growth. BCC is caused after long-term exposure to the sun or
occasional intense episodes that lead to sunburn. There are different therapeutic options after being diagnosed with NMSC. Electro-desiccation of a tumor has cure rates of 95%. Other procedures include tissue removal by surgery, cryosurgery, laser surgery, topical medication, radiation, and among others.

**MELANOMA**

Melanoma accounts for almost 10,000 deaths each year in the US alone, despite representing a small fraction of the total number of skin malignancies (Bristow, Casil et al. 2013). Melanoma, derived from melanocytes, is usually curable at early stages. However, once it advances and invades other tissues, it is generally resistant to cancer treatments. It is prone to spreading throughout the body from its site of origin (most frequent in the epidermis). For a variety of reasons, the prevalence of melanoma has been steadily increasing in Western countries for decades. Whereas only one in approximately 1,500 Americans were diagnosed with melanoma in his/her lifetime in the 1930’s, today that number has increased to roughly one in sixty people. Risk factors include family history of skin cancer, weakened immune response, moles, and sun exposure. There are two types of moles: benign moles and atypical moles, also known as dysplastic nevi. Even without family history, individuals with a high number of moles face a high risk of developing melanoma.

**MELANOMA PROGRESSION**

Most melanomas are derived from moles (nevi). At the molecular level, dysplastic nevi have an 80% frequency in mutations of BRAF, an oncogene that controls melanocytes cell growth (Fig. 1-4). Specifically, $\text{BRAF}^{V600E}$ leads to an increase in cell proliferation followed by cell senescence triggered by CDK4 activation, a regulator of cell cycle (Bertolotto 2013, Munoz-Hidalgo, Lopez-Gines et al. 2014). CDK4 loss leads to a radial phase growth in the progression of melanoma and, PTEN mutation leads to the activation
Figure 1-4. The progression of skin cancer.

Benign nevi show a BRAF mutation and activation of the MAPK signaling pathway. Atypical dysplastic nevi show loss of cyclin dependent kinase inhibitor (CDKN2A) and PTEN leading to an impaired cell cycle control. The growth phase of melanoma is characterized by up-regulation of cell adhesion signaling pathway. Other genes that loss regulated signaling are E-cadherin, N-cadherin, MMP-2 and TRPM1 a melanocyte-specific gene melastatin 1 (Miller and Mihm 2006).
of PI3K-AKT pathway that favors early stages of invasive melanoma. The activation of E- 
cadherin and WNT5A lead to the invasion into the dermis, the vertical growth phase. At 
this point, the aggressiveness of the cells lead to metastatic effects due to the loss of 
regulation of cellular proliferation, cell survival and apoptosis pathways.

Current therapeutic treatment for patients with melanoma is an initial procedure involving 
the surgical removal of the localized tumors. However, for specific cases, a physician 
might recommend a round of chemotherapeutic drugs targeting different oncogenes such 
as BRAF and MEK. The use of vemurafenib (Grimaldi, Cassidy et al. 2014), a BRAF 
inhibitor and trametinib a MEK inhibitor (Yajima, Kumasaka et al. 2012) are increasingly 
used in treatment of melanoma. Usually, these treatments are recommended for advance 
stages of melanoma leading to a better prognosis for survival. However, only a percentage 
of melanoma cases have mutations in BRAF, restricting therapeutic options for patients.

Melanoma occurs roughly twenty times more frequently in light-skinned persons 
compared to dark-skinned individuals (Aubin, Humbey et al. 2001). The incidence of 
melanoma in the United States has increased dramatically over the last several decades, 
particularly among fair-skinned individuals. Strong molecular and epidemiologic evidence 
supports the hypothesis that UV radiation is a major mutagenic environmental carcinogen 
responsible for melanoma (Gallagher, McLean et al. 1990, Kraemer, Lee et al. 1994, 
Wang, Yu et al. 2009, Pleasance, Cheetham et al. 2010, Parkin, Mesher et al. 2011, 
Wang, Smith et al. 2014). The role of UVA in melanoma formation is suggested by the 
basis of rising melanoma incidence over the last several decades and sunscreen 
use in the 1980s when only UVB-blocking sunscreens were used. UV exposure is thought 
to be a causal factor in the majority of melanoma cases. Clearly the more UV a person is 
exposed to (particularly strong intermittent doses such as those that cause sunburns), the 
higher his/her risk of melanoma.
Melanoma risk can be determined by the amount of sunlight exposure, occupational and recreational outdoor activities, amount of clothing/sun protection worn as well as proximity to the equator and altitude. However, a contributor factor for melanoma of increasing importance is the use of artificial UV (Dore and Chignol 2012). Proliferation of tanning beds use has played a role in this increase (Fisher and James 2010, Weinstock and Fisher 2010). There are more than one million people in United States of America using tanning beds per day (Spencer and Amonette 1998, Grimaldi, Cassidy et al. 2014). Several studies have estimated that indoor tanning bed use before the age of thirty-five, for example, increases lifetime risk of melanoma by as much as 75% (Schulman and Fisher 2009, Karagas, Zens et al. 2014). Even more than chronic lifetime UV exposure, melanoma risk seems particularly linked with sunburns (Pfahlberg, Kolmel et al. 2001), especially those early in life (Lew, Sober et al. 1983, Autier, Dore et al. 1998).

OXIDATIVE INJURY
The role of oxidative injury in the skin has been studied (Bickers and Athar 2006, Svobodova, Zdarilova et al. 2007, Piao, Ahn et al. 2014). Long exposure to UV radiation increases risk of keratinocytes malignancies (Potter, Gohde et al. 2000). Consequently, UVA has been found to have a role in the increased production of ROS (reactive oxygen species) in the skin. (Nataraj, Black et al. 1996) ROS are oxygen-like radical anions and molecules that due to their unstable electrons are very reactive. ROS are identified as superoxide radical $\text{O}_2^-$, hydroxyl radical $\text{OH}^-$ and hydrogen peroxide, $\text{H}_2\text{O}_2$. Similar to ROS, reactive nitrogen species (RNS) such as nitric oxide (NO) and peroxynitrite (OONO$^-$) increase the generation of oxidative stress. Oxidative stress is an imbalance in the generation of ROS and the antioxidant enzymes in the cells. Figure 1-5 shows a simplified scheme of the location of these species in the cell. Antioxidant enzymes are the main
UV induces a variety of free radical and oxidative molecules, which because of their chemical reactivity damage lipids, proteins and nucleic acids. Antioxidant enzymes mediate the removal of ROS, with different enzymes functioning in specific compartments (e.g. MnSOD localized to mitochondria). If not removed, ROS may react with DNA and other cell signal proteins, impairing their function. GSH, Glutathione. ECSOD, Extracellular Superoxide dismutase. Cu/Zn SOD, copper/zinc superoxide dismutase. MnSOD, Manganese Superoxide dismutase.

Figure 1-5. Antioxidant enzymes and oxidative stress.
regulators of the levels of ROS, acting to minimize ROS-mediated formation of DNA and proteins adducts and impairment of cellular function.

ROS are produced by cells during normal metabolic activities such as mitochondrial oxidative phosphorylation. Without inactivation, ROS can damage macromolecules including lipids, proteins and DNA. UV, particularly longer-wavelength UVA, is a well-known inducer of ROS, and UV-induced oxidative stress may be an important contributive factor for melanoma (Bossi, Gartsbein et al. 2008, Afanas'ev 2010, Choi, Uehara et al. 2012). ROS can inappropriately activate signaling pathways, interfere with genome maintenance, and affect apoptosis. Numerous studies have tested the effects of solar radiation and oxidative stress on the skin (Hu 2005, Poljsak and Dahmane 2012, Gabe, Osanai et al. 2014), and oxidative stress has been linked to age-related loss of skin elasticity (Langton, Sherratt et al. 2010, Mahmood, Akhtar et al. 2011, Naylor, Watson et al. 2011), defective cellular signaling (Prunier, Masson-Genteuil et al. 2012) and photo-aging (Stohs 1995, Lee, Cho et al. 2012).

ANTIOXIDANT ENZYME EXPRESSION

The term oxidative stress combines the excess of ROS with lower levels of antioxidant enzymes. The major antioxidant in most types of cell is glutathione (GSH). The role of GSH is to facilitate the depletion of H₂O₂ to H₂O. GSH is oxidized by glutathione peroxidase, GPX. GPX takes GSH and converts it to GSSG in order to reduce H₂O₂ to H₂O. Then, GSSG is recycled by glutathione reductase, GSR. GSR together with the co-factor NADPH produces GSH and NAD(P)⁺. Another antioxidant enzyme that controls the levels of H₂O₂ is catalase. Catalase is a nuclear-encoded protein that is located in peroxisomes and its levels increase after UV exposure (Schallreuter, Moore et al. 1999) in melanocytes (Song, Mosby et al. 2009, Kadekar, Chen et al. 2012). When there is depletion of GSH due to an increase in the levels of ROS, there is activation of the
transcription factor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Fig. 1-6) (Kokot, Metze et al. 2009). Nrf2 regulates the expression of glutamate cysteine ligase, GCLC, the enzyme that controls the catalytic limiting step for the synthesis of GSH. GCLC is known as γ-glutamyl cysteine synthase (Gipp, Chang et al. 1992). Therefore, there is recovery in the expression of GSH in a functional cell. Also, Nrf2 is involved in the regulation of GSR and glutathione-S-transferase, GSTA. GSTA is involved in the reduction of ROS-induced oxidized proteins (Kokot, Metze et al. 2009). The concentration of GSH decreases with skin tumor progression (Engin 1976, Bickers and Athar 2006). Levels of SOD are decreased in basal cell carcinoma (Nakagami, Inamura et al. 1991). As expected, several studies have found that there is an increase in the oxidative state of skin cancer cell lines (Engin 1976, Nakagami, Inamura et al. 1991, Liebler and Burr 2000, Schallreuter and Wood 2001). Taken together, the regulation of oxidative stress is the key to decreasing the burden of UVA-induced oxidative stress.

SUPEROXIDE DISMUTASE

Superoxide radical (O$_2^-$) is generated by photoexcitation of triplet oxygen (O$_2$) that by transferring an electron to an intermediate singlet oxygen specie (O$_2$) induces the formation of O$_2^-$ (Mayeda and Bard 1974). Specific antioxidant enzymes that decrease levels of O$_2^-$ radicals are called superoxide dismutases (SOD). They are found among different locations in the cells but their common role is the removal of superoxide radicals from the cell. Cu/ZnSOD is found in the cytoplasm and mitochondrial membrane. ECSOD is found anchored in the plasma membrane and its role is to regulate O$_2^-$ radicals produced during lipid peroxidation such as 4-hydroxy-nonenal and malondialdehyde. In addition, there is endogenous production of O$_2^-$ by the electron transport chain in the mitochondria. Levels of O$_2^-$ in the mitochondria are depleted by MnSOD converting O$_2^-$ to H$_2$O$_2$ for further conversion to H$_2$O by GPX or catalase. Polymorphisms in SODs are associated with
Figure 1-6. The signaling pathway of Nrf2 and NfkB after cell injury.

Endogenous and exogenous activators induce the release of Nrf2 from its inhibitor keap1 leading to keap1 degradation. Nrf2 translocates to the nucleus and binds to antioxidant response element (ARE) promoting the expression of different genes. Some of these genes are regulators of glutathione synthesis, the transporters MRP 1, 3, & 4 among other antioxidant genes. On the other hand, IκBα inhibits NF-κB in the cytoplasm. The phosphorylation of IκBα leads to its degradation and further phosphorylation of NF-κB. NfkB translocates to the nucleus binding to the κB site in DNA promoting the regulation of apoptotic genes, cell cycle regulators inflammatory signaling and immune responses.
cardiovascular and neurodegenerative disorders (Berneburg, Gremmel et al. 2005, Boutte, Woltjer et al. 2006, Zhang, Yang et al. 2009, Lai, Xu et al. 2013). Cu/ZnSOD and ECSOD are inhibited by H$_2$O$_2$; MnSOD is inactivated by peroxynitrite. The gene expression of SOD is regulated by nuclear factor kappa B, NF-$\kappa$B (Dhar, Xu et al. 2010) (Fig. 1-6). NF-$\kappa$B is inhibited in the cytoplasm by inhibitor kappa beta, IK$\beta$ (Dhar and St Clair 2012). NF-$\kappa$B is activated by UV-mediated MAP Kinase pathway that phosphorylates IK$\beta$. This inhibits IK$\beta$ and releases NF-$\kappa$B to translocate to the nucleus and together with a co-regulator, activates the expression of many gene-encoding receptors, cytokines and antioxidant enzymes such as SOD. IK$\beta$ inhibits NF-$\kappa$B translocation to the nucleus. Interestingly, the receptor of 1α,25-Dihydroxyvitamin D3, the active form of vitamin D, interacts with IK$\beta$ inhibiting NF-$\kappa$B activity (Chen, Zhang et al. 2013). UV induces the generation of 1α,25-Dihydroxyvitamin D3 and by activating its receptor, stabilized IK$\beta$ and induces an attenuation of NF-$\kappa$B nuclear translocation. Nonetheless, there is positive feedback for the degradation of IK$\beta$ upon the presence of endogenous or exogenous cellular stress activators. The kinetics for expression of several antioxidant enzymes at the transcriptional level usually is within hours (Lundqvist, Yde et al. 2014).

SKIN AGING AND ANTIOXIDANT DEFENSES

Because it triggers cellular damage pathways, oxidative stress activates cellular senescence, which is thought to directly lead to photo-aging (Velarde, Flynn et al. 2012, Yun, Kwon et al. 2012, Sakura, Chiba et al. 2013). Cellular senescence is associated with a reduced capacity to divide and proliferate, sometimes in conjunction with the shortening of telomeres (Kashino, Kodama et al. 2003, Yokoo, Furumoto et al. 2004, Davis, Wyllie et al. 2007, Makrantonaki and Zouboulis 2007). Yokoo et al. found that exposing cells to a pro-oxidant agent (H$_2$O$_2$) impaired telomerase function which eventually resulted in telomere shortening, decreased proliferation, and cellular enlargement (Yokoo, Furumoto
Wrinkling of the skin is one of the most overt signs of photo-aging, and UV exposure can induce wrinkling over time (Raschke, Koop et al. 2004, Cornacchione, Sadick et al. 2007, Felippi, Oliveira et al. 2012, Kong, Shi et al. 2013). Though the molecular mechanism(s) of wrinkling are likely to be complex, UV exposure may reduce elastic properties of the skin to alter the three-dimensional structure of elastic fibers (Imokawa 2009).

There is a lot of interest in the study of antioxidant enzyme depletion leading to skin aging. The constant exposure to UV, allows the skin to show early symptoms of aging such as wrinkles, dryness and stiffness. Several natural products may reduce UV-induced oxidative damage. One mechanism of action of these natural agents is in the activation of the ascorbic acid pathway and reducing the levels of lipid peroxidation (Villacorta, Zhang et al. 2007). Another mechanism of antioxidant control is the activation of the Nrf2 pathway that has been implicated as a beneficial effect of resveratrol (Soeur, Eilstein et al. 2015). The use of resveratrol in human keratinocyte induces accumulation of cellular glutathione. Similar studies in mice showed that the main component in licorice root, 18B-glycyrrhetinic acid, induces expression of SOD and GPX (Kong, Shi et al. 2013). The use of natural flavonoids showed a beneficial effect against UV-induced inflammation (Masnec, Kotrulja et al. 2010, Nichols and Katiyar 2010). For example, flavonoids such as solidago induced anti-inflammatory signaling in reticulo-endothelial systems (Apati, Houghton et al. 2006, Wu, Takahashi et al. 2007, Lutz, Kulshrestha et al. 2014).

MELANOCORTIN 1 RECEPTOR (MC1R)

The MC1R is a 7-transmembrane protein located in the plasma membrane of melanocytes. MC1R is located on chromosome 16q24.3 in human and in mouse chromosome 8: 123,407,107-123,410,744. It is a 34.7 kilodalton transmembrane Gs-coupled hormonal receptor (Smith, Box et al. 2001). The role of MC1R is to control the
ratio of eumelanin and pheomelanin synthetized in the skin and hair of many species. In mice, MC1R deficiency on C57BL/6J mice causes red/pink blonde hair compared to a dark/black heavy pigmented complexion in wild-type state. The over-expression of MC1R causes a heavily melanized epidermis that might lead to deficiency in vitamin D production that requires UV-exposure for its biosynthesis (Slominski, Kim et al. 2013). Polymorphisms of MC1R were selected in world populations as people moved from the equator to geographical areas that UV is less rich to prevent 1α,25-Dihydroxyvitamin D3 (vitamin D) deficiency and rickets. For example, in Northern America, loss of function of MC1R is common. The most common MC1R polymorphism are known as red hair color (RHC) mutations Asp294His (D294H), Arg151Cys (R151C) and Arg160Trp (R160W) (Davies, Randerson-Moor et al. 2012, Pellegrini, Fargnoli et al. 2012). These mutations increase the incidence risk for sunburn and an increase prevalence of melanoma by four fold.

THE MC1R PATHWAY

The endogenous agonist ligand of MC1R is α-melanocyte stimulating hormone, α-MSH. The binding of α-MSH to MC1R leads to the activation adenylate cyclase (AC) (Rouzaud, Kadekaro et al. 2005). Then, AC converts a molecule of ATP to cAMP working as a second messenger protein with many roles in cellular signaling. This leads to the activation of the cAMP respond element-binding protein (CREB) to translocate to the nucleus inducing microphthalmia inducer transcription factor, MITF. This is a critical regulator for melanocyte differentiation and melanin production (Fig. 1-7).

THE TRANSCRIPTION FACTOR MITF

MITF is a transcriptional factor that recognizes E-box and M-box sequences in the promoter regions of target genes (Hoek, Schlegel et al. 2008). MITF regulates the expression of Tyrosinase, and Tyrosinase related proteins that are the main regulators in the synthesis of eumelanin. The accumulation of cAMP induces pro-differentiation and
Figure 1-7. The adaptive tanning response.

Upon UV irradiation, the DNA damage response lead to the activation of the expression of POMC in keratinocytes. POMC is cleaved, producing three products, among them α-melanocyte stimulated hormone (α-MSH). Activated by its agonist α-MSH, MC1R promotes cAMP second messenger generation which induces melanocyte differentiation and survival pathways involving PKA, CREB and MITF In this way, cAMP induces both melanin production and antioxidants that reduce cellular ROS. cAMP, cyclic adenosine monophosphate. PKA, protein kinase A. pCREB, phosphorylated cAMP response binding element. ROS, reactive oxygen species. MITF, microphthalmia (Mitf) transcription factor.
survival signaling in melanocytes in addition to high levels of MITF. Studies performed in B16 mouse melanoma cells confirmed a link between MITF expression and melanin production and stimulation of NADPH oxidase 4 (Nox4). Liu and colleagues showed that APE-1 induces MITF leading to cell survival (Liu, Fu et al. 2009). Low levels of cAMP led to lower expression of MITF and the synthesis of the oxidation-prone pheomelanin. Waardenburg syndrome (WS) is a genetic disorder arising from the neural crest and among its defects, there is deafness and pigmentation abnormalities. Deficiency in MITF expression has been identified in WS (Grill, Bergsteinsdottir et al. 2013). Kim and colleagues found that ROS induced ERK signaling increases MITF degradation (Kim, Park et al. 2014).

THE LIGANDS OF MC1R

α-MSH is produced in keratinocytes and is a metabolite of the pro-opiomelanocortin pro-peptide (POMC) (Hadley and Haskell-Luevano 1999). DNA damage pathways, including p53, induce POMC expression after UV injury. α-MSH is a small peptide with only 13 amino acids (HOOC-SYSMEHFRWGKPV-NH2) (Sahm, Olivier et al. 1994). However, among soluble ligands of MC1R, α-MSH does not have the highest binding affinity. There are other products that are cleaved from POMC. These ligands are β-MSH, γ-MSH, β-endorphin and adrenocorticotropic hormone (ACTH) and they not only regulate weaker levels of cAMP with MC1R but also bind to other melanocortins expressed in the skin. There are two peptides identified that limit or inactivate MC1R signaling in the skin: agouti signaling protein (ASIP) and β-defensin 3 (BD3). Both β-defensin and agouti inhibit α-MSH binding MC1R by blocking its active site (Swope, Jameson et al. 2012). ASIP has higher affinity for MC1R than α-MSH and can directly bind and down-regulate the production of cAMP (Voisey and van Daal 2002, Ito and Wakamatsu 2011). BD3 was identified as an antimicrobial peptide and it has higher affinity to MC1R than ASIP (Abdel-Malek and Supp
2008, Swope, Jameson et al. 2012, Benato, Dalla Valle et al. 2013). It is important to remember that although MC1R has a protective effect in the skin, there is tight regulation of its activation and downstream targets. Although MC1R RHC mutations are known to impair MC1R signaling, there are different ligands that have a role as antagonists leading to MC1R inactivation. There is little known about the role of these antagonists but they might be present as a regulatory aspect to limit the production of melanin only when required. Nonetheless, MC1R is a key receptor for the regulation of adaptive pigmentation in the epidermis and its activation and regulation in the context of whole skin is likely to be complex.

MC1R DEFICIENCY

MC1R activates the adaptive pigmentation pathway. The phenotype of individuals lacking MC1R show a fair-skin complexion leaving the skin to the exposure of hazardous UV doses that could be blocked by the accumulation of more of eumelanin. This leads to DNA damage that contributes to melanocyte mutagenesis. Several studies show a direct impact of MC1R deficiency in the level of UV-damage products in melanocytes (Jarrett, Horrell et al. 2014). MC1R defective melanocytes are not able to repair UV damage efficiently leading to higher risk of mutagenesis skin-prone population. There are limited studies about the role of MC1R in the regulation of UV-induced oxidative injury. Mitra and colleagues reported that melanocytes with mutated MC1R lead to melanoma formation without UV exposure by the oxidative damage caused by the expression of pheomelanin (Mitra, Luo et al. 2012). The MC1R protein is also a major regulator of melanoma risk in humans (Valverde, Healy et al. 1996, Rees 2000, Box, Duffy et al. 2001, Kennedy, ter Huurne et al. 2001, Sturm 2002, Galore-Haskel, Azizi et al. 2009, Hoiom, Tuominen et al. 2009, Ibarrola-Villava, Fernandez et al. 2010, Scherer, Nalls et al. 2010, Cust, Goumas et al. 2012, Ghiorzo, Bonelli et al. 2012), therefore I have been interested in the mechanisms
by which MC1R signaling protects melanocytes against UV-induced oxidative stress and antioxidant defenses.

**K14-SCF TRANSGENIC MOUSE MODEL**

In humans, melanocytes are localized in the stratum basale above the basal lamina of the epidermis (Fig 1-1). The survival and migration of melanocytes is regulated by a receptor tyrosine kinase cKIT or KIT receptor (Murakami, Matsumoto et al. 1995, Herraiz, Journe et al. 2011, Azevedo, Horvath et al. 2013). This receptor controls melanocyte development, migration and survival and it is activated by a stem cell factor (**SCF**) also known as KIT ligand (Guo, Jie et al. 2014). The cKIT signaling pathway promotes phosphorylation of MITF leading to its short-lived activation and further degradation (Torres-Cabala, Wang et al. 2009). This regulates MITF expression after α-MSH signaling activates MC1R.

The use of mice as an animal model to investigate pigment-dependent physiology in the skin is limited because of innate differences between human skin and mouse skin. Whereas human skin maintains melanocytes in the epidermis throughout life (imparting melanin pigments to the epidermis), mouse skin is only transiently populated by melanocytes in the epidermis in the neonatal period. For adult mice, their melanocytes are located in the hair follicle at the dermis. This feature results in a fur coat color rather than skin pigment. In addition, during postnatal development, melanocytes can be found in the ears, tail and paws. However, these melanocytes cannot be retained due deficiency in stem cell factor (**SCF**) expression leading to inactivation of cKIT receptor.

One approach to be able to utilize mice to study pigment effects (such as cAMP rescue of melanization) is to transgenically express melanocyte growth factors (such as **SCF**) in the epidermis constitutively throughout life. We had reported the use of a transgenic C57BL/6 mouse model that resembles human skin. In this model, the keratin 14 (**K14**) **SCF**
transgene, which is constitutively expressed in keratinocytes, retains melanocytes in the epidermis. This model features localization of melanocytes in the epidermis and accumulation of black/dark pigmented melanin in the skin of wild-type Mc1rE/E Tyr+/+ mice. On the other hand, there is production of a red/light pigmented melanin in Mc1r<sup>e/e</sup> Tyr<sup><i>/+</i></sup> mice due to deficiency in MC1R signaling. There is an albino mouse Mc1r<sup>E/E</sup> Tyr<sup>c<sub>2j/c2</sub></sup> that signals MC1R, but it is deficient in tyrosinase expression, and it is unable to produce melanin. Finally, the albino extension mouse is Mc1r<sup>e/e</sup> Tyr<sup>c<sub>2j/c2</sub></sup> unable to produce melanin and it is deficient for MC1R signaling. This mouse model reflects three possible phenotypes in human skin complexion.

FORSKOLIN

There are numerous options for the induction of sunless tanning response in the skin. Among them, a natural product called forskolin has generated interest from researchers and general public. Forskolin, identified in 1974 by a Finnish botanist named Forskal, is a bioactive constituent of the root portion of the *Coleus forskohlii* (*Plectrantus barbatus*) plant (Lukhoba, Simmonds et al. 2006) and it is cultivated in South East Asia that included countries like India, Nepal, Sri Lanka, and Thailand. Scientists characterized it because the plant from which it was derived had long been used in traditional Ayurvedic medicine for a range of disorders and diseases. Forskolin, also known as Coleonol, has a unique heterocyclic structure that classifies the molecule as part of the labdane diterpene family (Fig 1-8).

The crude root forskolin extract has many components including alkaloids, phenols, tannins and histamines (Alasbahi and Melzig 2012). The forskolin extract has been reported to induce hypotension (De Vries, Amdahl et al. 1988, Lindgren, Crossley et al. 2011), blood thinness (Hayashi and Sudo 2009), mast cell degranulation (Cheli, Giuliano et al. 2012) and stimulation of adenylyl cyclase (Pinto, Papa et al. 2008). Forskolin has
Figure 1-8. The structure of forskolin.

The compound, which molecular formula is $C_{22}H_{34}O_7$ and is known as forskolin, can bind to 8 of the 9 isoforms of adenylate cyclase (AC). AC is activated by G-protein to catalyze the conversion ATP to cAMP. Pharmacologic activation of AC using forskolin decreases receptor agonists’ desensitization that down-regulate AC signaling cascade..
been study for its many beneficial physiological effects on skin conditions such as psoriasis and eczema. Recent studies attribute positive effects to treat weight loss (Geller, During et al. 1993, Doseyici, Mehmetoglu et al. 2014) and to alleviate symptoms associated with painful menstrual periods (da Conceicao, de Oliveira et al. 2012). Together with antibiotics, forskolin has been used for the treatment of urinary tract infection (Doseyici, Mehmetoglu et al. 2014). Forskolin has been studied as a vasodilator for cardiovascular diseases to prevent hypertension (Enomoto, Yoshihisa et al. 2011). However, oral administration of forskolin also induces side effects such as headaches and accelerated heart rate (Galeotti, Ghelardini et al. 2001). These effects have been linked to an increase in bleeding episodes (Onoue and Katusic 1998).

At the molecular level, forskolin is able to bind to adenylate cyclase (AC), an enzyme responsible for the production of the second messenger cAMP from ATP. The AC isoforms are restricted to specific tissue (brain, liver, lung, uterus, testis and muscle) and excitable cell types (endothelial cells) (Sunahara and Taussig 2002). There are nine isoforms of AC and the binding of G-protein subunits regulates its activation. Forskolin is able to mimic the G-protein and it binds at the catalytic site of AC to allow ATP access and transformation to cAMP (Cumbay and Watts 2004). Forskolin can bind to all AC isoforms except AC9 (Cumbay and Watts 2004). Once activated AC changes its conformation to allow the binding of ATP. ATP is converted to cAMP which is a second messenger inducer for a numerous of intracellular signaling pathways. There are pharmacologic drugs available that can directly increase cAMP levels such as forskolin and rolipram, a phosphodiesterase (PDE) inhibitor. PDE is known to mediate the degradation of cAMP. These drugs can activate the pathway independent of MC1R status. However, a pharmacologic formulation of forskolin is able to penetrate the skin and is efficiently absorbed transdermally.
FORSKOLIN-MEDIATED MELANIN RESCUE

As discussed previously, MC1R triggers the activation of adenylate cyclase for the production of cAMP, activation of MITF, and synthesis of protective eumelanin. However, deficiency in MC1R signaling induces low levels of cAMP and production of pheomelanin. However, MC1R RHC mutation and inhibitors do not affect the mechanism mediated by forskolin since forskolin is able to bypass the receptor dependent signaling (Abdel-Malek and Supp 2008). We, together with other laboratories, have utilized forskolin as an adenylate cyclase activator. Using our mouse model, topical administration of forskolin induced eumelanin accumulation in the skin of $K14$-$SCF$ $Mc1r^{e/e}$ $Tyr^{+/-}$ extension mice compared with non-transgenic treated and untreated mice. After chronic stimulation of cAMP daily for 21 days leading to accumulation of melanin, these mice showed no changes in body weight and liver size (Spry, Vanover et al. 2009). However, there was an increase in epidermal thickening (Scott, Christian et al. 2012). Forskolin induced expression of the keratinocyte growth factor, leading to keratinocyte accumulation in the epidermis.

Therefore, among its other mechanisms, forskolin-induced skin darkening is a target of cAMP production (D’Orazio, Nobuhsisa et al. 2006). Topically-applied forskolin seems to be systemically absorbed, leading to systemic cAMP stimulation in the mice as evidenced by darkening of skin in other sites. Previously, we reported that the most darkening of the skin was obtained after 2 weeks of daily treatment with forskolin and persist as long at the topical application was continued. In fair-skin individuals, unless there is constant application of forskolin, the darkening of the skin fades away and the skin returns to its normal shade. This means that the $K14$-$SCF$ by itself does not rescue melanin production of the skin. The mechanism of skin darkening requires stimulation of the adaptive pigmentation pathway for the production of melanin and further deposition in
keratinocytes. If there is pharmacologic stimulation of melanin production, we can study the relation between the stimulation of MC1R and the expression of UV-mediated DNA damage products after darkening of the skin. In addition, this method is useful to study DNA repair mechanisms that can be addressed as targets for the therapeutic application and prevention of UV-mediated skin mutagenesis.

MELANIN-INDEPENDENT EFFECTS

There are other effects mediated by forskolin that are melanin-independent. The solute carrier family 24 member 5 (SLC24A5) is a regulator of the ratio of dark and light pigmented melanin in the skin. Cheli and colleagues were able to show the up-regulation of this transporter after an increase of cAMP in forskolin treated B16 mouse melanoma cells (Cheli, Luciani et al. 2009). This regulation has an important role in melanosomes alkalization and regulation melanin synthesis. Spindler et al. studied the role of cAMP in the loss of keratinocytes cohesion and further blister formation in transformed keratinocytes and neonatal mice (Spindler, Endlich et al. 2011). Forskolin together with rolipram, prevented the loss of desmoglein, a calcium-dependent adhesion molecule, preventing the loss of cell adhesion. Kokot and colleagues study the effect of the MC1R/cAMP pathway in the regulation of antioxidant enzymes expression (Kokot, Metze et al. 2009). The use of α-MSH induces Nrf2 and Nrf2-induced gene expression in human keratinocytes. Nrf2 is a transcription factor for key antioxidant enzymes such as glutathione and glutathione regulators. Forskolin shows the same effect as α-MSH inducing expression of Nrf2 by increasing cAMP production and CREB binding to the promoter region of Nrf2 (Kokot, Metze et al. 2009). Furthermore, forskolin increases the removal of cyclobutane pyrimidine products and 6-4PP caused by UVB exposure (Jarrett, Horrell et al. 2014). A proposed mechanism of action includes the modulation of DNA damage repair factors such as xeroderma pigmentosum complement group A (from the

RATIONALE

UV exposure is one of the most important environmental health hazards, clearly causative for age-related skin changes such as wrinkling, pigmentary changes, thinning and carcinogenesis. Because of complex societal factors, UV exposure may actually be increasing through increased occupational and recreational activities including indoor tanning. There is emerging evidence implicating MC1R and cAMP signaling in regulating antioxidant proteins. Using keratinocytes transfected with MC1R, Henri et al. reported lower cellular levels of ROS after pharmacologic activation MC1R/cAMP pathway and higher levels of ROS when PKA was pharmacologically inhibited (Henri, Beaumel et al. 2012). In other work using human melanocytes, Song and colleagues found that α-MSH-induced MC1R signaling increased levels of catalase after UV exposure (Song, Mosby et al. 2009). Finally, Kaderaro and coworkers reported that cAMP stimulation reduced levels of hydrogen peroxide, an important ROS, in human melanocytes after UV exposure (Kadekaro, Chen et al. 2012).

Loss of function MC1R polymorphisms impedes accumulation of protective melanin in the skin. MC1R deficiency is linked to skin cancer incidence. As we learn more about innate signaling mechanisms that regulate natural antioxidant defense pathways in the skin such as the MC1R hormonal axis, new approaches are being designed to exploit these signaling pathways to delay or even prevent free-radical induced symptoms of aging. Use of natural extracts such as forskolin enhance protection against UV-induce molecular damage to the skin. cAMP-induced melanin deposition and antioxidant induction may prove to be an important therapeutic opportunity to reduce UV-mediated pathologies.
PROJECT OBJECTIVES

In this study, I explore the role of the MC1R pathway in protecting against UV-induced sunburn and providing skin protection by enhancing expression of antioxidant enzymes in the skin. We had previously demonstrated that the topical application of a cAMP activator highly activates the MC1R pathway in Mc1r<sup>e/e</sup> mice.

This study addresses the following issues in two chapters:

**Chapter 2:** MC1R signaling pathway promotes epidermal pigmentation and protect against sunburn.

**Chapter 3:** MC1R signaling pathway increases MnSOD levels in the mitochondria and does not affect mitochondrial oxidative phosphorylation.

In chapter two, I hypothesize that a short-term topical activation of MC1R/cAMP pathway decreases UV sensitivity in Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> mice. Our laboratory previously reported the development of a K14-SCF mouse model with a robust deposition of black melanin pigment due to the presence of epidermal melanocytes. Mc1r-defective fair-skinned mice resulted in an accumulation of eumelanin and a UV-protected phenotype against skin sunburn. In addition to this phenotypic effect, I studied the role of the MC1R pathway to protect the skin at the molecular level.

In chapter three, I hypothesize that MC1R signaling protects against oxidative stress by the enhancement of antioxidant cellular defenses. These results provided an insight about a possible mechanism of MC1R signaling pathway to control biosynthesis and regulation of antioxidant enzymes by enhancing their gene expression. Moreover, I explore the protein levels of the MnSOD in human melanocytes. The results suggest that increases MnSOD may not involve transcriptional up-regulation but rather MnSOD transport and/or stability. Furthermore, I studied if there was any protective effect in mitochondria metabolism after activation of the MC1R/cAMP signaling pathway.
CHAPTER 2

MC1R signaling pathway promotes epidermal pigmentation and protect against sunburn.

This chapter is based on work published as Amaro-Ortiz, A., Vanover, J.C., Scott, T.L., D'Orazio, J.A. Pharmacologic Induction of Epidermal Melanin and Protection against Sunburn in a Humanized Mouse Model. J. Vis. Exp. (79), e50670, doi: 10.3791/50670 (2013).

INTRODUCTION

The most deadly form of skin cancer is melanoma. In the United States, there is a dramatic increase in the incidence of melanoma among light-skinned individuals. Epidemiologic evidence showed a 20 % increase in the frequency of melanoma in fair-skinned individuals compared to dark-skinned individuals. UV radiation is a major environmental factor that contributes to the increased risk to develop skin cancer. Long exposure to solar radiation and the constant use of tanning beds increase the intensity of UV exposure to the skin. UV radiation induces direct and indirect molecular damage that can lead to genetic mutations. These mutations lead to proliferative skin cells that spread to other parts of the body and produce the generation of tumors. In addition, early life episodes of skin sunburn have been linked to an increase in melanoma risk. Still, skin pigmentation has a mayor role to determine the risk of developing melanoma.

The ratio of dark eumelanin to reddish pheomelanin varies among individuals. I focused on fair-skinned individuals with low levels of eumelanin because more UV photons can penetrate into the skin. There is a direct correlation between melanoma risk and the signaling ability to “tan” following UV exposure. The activation of the melanocortin 1 receptor (MC1R) pathway increases the levels of protective eumelanin in the skin. The MC1R is a G-protein couple receptor located in the plasma membrane of melanocytes.
and mediates activation of adenylate cyclase to increase production of cAMP. The secondary messenger cAMP allows activation of main regulators of melanin biosynthesis as previously discussed. UV mediates MC1R activation allowing melanocytes differentiation and melanin production. Melanin is a complex polymer produced in melanocytes is deposited in keratinocytes to protect the skin against exposure to higher and hazardous UV doses. The endogenous ligand of MC1R is the α-melanocytes stimulating hormone, α-MSH. The ligand is a tripeptide that can activate the MC1R and induce the tanning response thus reducing UV-induced DNA damage in human melanocytes. However, the down-regulation of the MC1R pathway increases the levels of non-protective pheomelanin in the skin. I was interested in the mechanism by which MC1R mediates melanocyte protection against UV-exposure. I used extension mice (Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>) that model the fair-skinned humans with decreased MC1R signaling. This transgenic model constitutively expressed K14 stem cell factor (SCF) allowing epidermal melanocytes to be retained at the basal layer of the epidermis. However, non-transgenic mice maintain its melanocytes on the dermis in hair follicles.

Our laboratory developed an animal model to address the mechanism of the MC1R pathway. For this study, the mice used were wild type mice (Mc1r<sup>E/E</sup> Tyr<sup>+/+</sup>) darker-skinned mice; extension (Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>) fair-skinned mice due to decreased MC1R signaling. Our previous research confirmed a melanizing effect of chronic topical treatments of forskolin correlating with increased UV-resistance in extension (Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>) K14-SCF animals. In this chapter, I demonstrate that short-term application of forskolin also rescues MC1R signaling pathway. Moreover, I measured the deposition of melanin pigment and tested protection against UV-induced sunburn by measuring the minimal erythematus dose, MED.
SPECIFIC AIM:
To study the rescue of MC1R signaling pathway using forskolin

a) To determine the role of forskolin after a short-term topical application.
b) To determine the deposition of melanin after MC1R stimulation.
c) To examine how MC1R activation protects the skin against sunburn.

METHODS AND MATERIALS
Protocols for murine experiments followed the guidelines for ethical conduct in the care and use of animals and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky (Protocol # 00768M2004).

MOUSE COLONY
4 to 12 week old C57BL/6 extension non-transgenic and K14-SCF transgenic extension males and females mice were used. The characteristic phenotype was blonde fur, pink skin, dark footpads and nose tip. The mice showed pheomelanotic fur, pheomelanotic epidermal skin (due to presence of interfollicular epidermal melanocytes).

REAGENTS AND MATERIALS
The following reagents were purchased commercially: Coleus Forskohlii 20% extract (Buckton Scott USA Inc., Princeton NJ); Depilatory cream Nair (Church & Dwight, Princeton, NJ); Xylazine (Anased Injection, Shenandoah, IA); Ketamine (Putney, St. Joseph, MO.); Isothesia Isoflurane (Butler Schein, Dublin, OH); Propyl glycol (Amresco, Solon, OH) and Ethyl Ethanol (Fisher, Waltham, MA.). The following materials were purchased commercially: Chromameter CR-400 and data processor (Konica Minolta, Ramsey, NJ); Electric Shears (Oster, Atlanta, GA); NIST Radiometer/Photometer Model IL1400A, International Light, Newburyport, MA), and Germicidal Hg Lamb UV-B (Westinghouse, Pittsburgh, PA).
PREPARATION OF FORSKOLIN EXTRACT FOR TOPICAL ADMINISTRATION WAS FROM A CRUDE ROOT OF THE PLECTRANTHUS BARBATUS (COLEUS FORSKOHLII) PLANT

The preparation of forskolin was made by solubilizing P. barbatus root extract 20% (ATZ Natural, NJ) The root extract is prepared at 40% weight/volume in a standard dermatologic base of 70% ethanol, 30% propylene glycol. After stirring for an hour at room temperature, the slurry was centrifuged (1,500 x g, room temperature, for 15 minutes). The solution was filtered through a 0.22µm cellulose acetate membrane to remove any residual insoluble material from the extract. The extract maintained biologic activity for months at room temperature.

PREPARATION OF C57BL/6 K14-SCF MICE FOR TOPICAL TREATMENTS

The mice were briefly anesthetized using intraperitoneal injection of a standard mixture of ketamine (Putney, St. Joseph, MO.) and xylazine (AnaSed, Shenandoah, IO.) (Typically 0.04ml per 10g body weight of a mixture of 10mg/ml ketamine and 1.0mg/ml xylazine). The dorsal fur was removed using electric shears equipped with a 0.25mm surgical preparatory head followed by chemical depilation by Nair (Church & Dwight, Princeton, NJ.). After 24 hours, the mice were treated in the dorsal skin with 400uL of 40% crude forskolin extract; vehicle control animals received 70% ethanol, 30% propylene glycol alone twice daily for 5 days (10 applications). Then, 48 hours after the last topical treatment, the mice were anesthetized with ketamine and xylazine so that UV sensitivity by calculation of “Minimal Erythematous Dose” (MED) could be determined. A UV-occlusive tape was placed on the back of the mice. The mice were placed in a UV source consisting of two Westinghouse F15T8UV-B lamps with a peak output of 313nm and a range of 280 to 370nm based on the UV transmission rate as measured by the UV Photometer. The UV exposure time was calculated for each desired dose based on the UV output of the source. The mice were monitored for 24 to 48 hours to look for discreet
areas of erythema (redness) or edema (swelling) corresponding to the anatomic sites exposed to the specific dose of UV irradiation. The skin findings were documented photographically. The skin color was measured by reflective colorimetry while the mouse was briefly anesthetized by inhaled isoflurane (Butlet Schein, Dublin, OH). A Minolta colorimeter was calibrated by placing the portable head on the standardized white surface provided with the colorimeter.

**STATISTICAL ANALYSIS**

The data was analyzed between cohorts of replicate samples (n = 3) by one-way ANOVA using the Bonferroni post-test (Graph Pad PRISM software). p values <0.05 were considered statistically significant.

**RESULTS**

**FORSKOLIN-INDUCED MELANIZATION OF FAIR-SKINNED MICE.**

I tested the rescue of the MC1R signaling pathway in the C57BL/6 *extension* non-transgenic and *K14-SCF* transgenic *extension* pheomelanotic (*Mc1re<sup>e</sup>, *Tyr<sup>+/+</sup>*) mice (Fig. 2-1A). The ears of the mice show the retention of melanocytes in the epidermis. The mice were treated twice daily for 5 days with either vehicle (70% ethanol, 30% propylene glycol) or 40% crude Coleus Forskohlii root extract (Fig. 2-2 B). The amount of melanization of the skin was dose dependent. The concentration of forskolin was 80uM per dose per application. The effects of topical application on the dorsal skin were inspected visually and using a reflective colorimeter (Fig. 2-2B). I reported an accumulation of robust epidermal darkening after the last application of the root extract in the C57BL/6 *K14-SCF* transgenic *extension* mice but not in the C57BL/6 *extension* non-transgenic mice. These results indicate the importance of the location of epidermal melanocytes in order to allow pharmacologic stimulation of melanin to be deposited in the keratinocytes located in the epidermis. Although the root extract contains plant photo-chemicals that contribute to its
color, there is no skin darkening in non-transgenic animals. Therefore, the dyeing effect from the drug has no contribution to the skin darkening (Fig. 2-2A). The topical treatment of forskolin showed an effect as early as two days and continued to a maximal darkening after several applications (Fig 2-2B).

**TOPICAL FORSKOLIN DECREASES UV SENSITIVITY.**

Next, I determined the effect of the topical application of forskolin on UV sensitivity by testing MED in C57BL/6 *K14-SCF* transgenic extension mice. I compared this group with non-transgenic mice as a control for the non-forskolin component of the root extract. The reflective colorimetric white-black scale L* value was $31.9 \pm 1.8 \text{ kJ/m}^2$ compared to $3.8 \pm 1.8 \text{ kJ/m}^2$. Actually, a dose of $30.0 \text{ kJ/m}^2$ did not generate erythema in the dorsal skin. This was expected since the mice show no obvious side effects after the scheduled 10 applications; thus, I concluded that twice-daily administration of forskolin induces a non-toxic and safe melanization. The MED was measured 2 days after the last topical application of forskolin, thus non-pigmentary effect of cAMP have no role in MED results (Fig 2-3A,B). Thus, whereas mean MED for *K14-SCF* extension mice treated for twice for 5 days with vehicle was $5.0 \pm 0.0 \text{ kJ/m}^2$, average MED for cohorts treated with topical forskolin was $>30.0 \pm 0.0 \text{ kJ/m}^2$. In fact, a dose of $30.0 \text{ kJ/m}2$ was insufficient to generate erythema in this experiment. There was no significant difference when I compared non-transgenic and *K14-SCF* transgenic extension treated with vehicle (70% ethanol, 30% propylene glycol). I reported an L* value of $3.3 \pm 1.4 \text{ kJ/m}^2$ compared to $5.0 \pm 0.0 \text{ kJ/m}^2$, respectively. Overall, forskolin induces epidermal melanization and provides a decrease in UV sensitivity in fair-skinned individuals.
Figure 2-1. Topical treatment of forskolin promotes skin darkening in fair-skinned extension.

(Mc1r<sup>e<sub>e</sub></sup>) mice photographs of C57BL/6 animals used in this study. Animals are genetically matched except at the melanocortin 1 receptor (Mc1r). Note that pigmentation is eumelanotic (black) when Mc1r is functional but pheomelanotic (blondish) when Mc1r is defective, as is the case with the extension (Mc1r<sup>e<sub>e</sub></sup>) mutant. Epidermal pigmentation depends on retention of interfollicular epidermal melanocytes in the skin by the K14-SCF transgene, and the skin darkening can easily be seen in the ears.
Figure 2-2. Twice daily application of Forskolin induces MC1R signaling.

(A) Photographs of extension (Mc1r

extension) K14-SCF or non-transgenic animals treated with 400uL of vehicle control (70% ethanol 30% propyl glycol) or 40% w/v (80 µM) forskolin applied twice daily to the shaved dorsal skin for 5 days, total of 10 applications. Skin color measurements by reflective colorimetry were performed for each group. Reflective colorimetry results are reported as mean (± SD) reflectometry units on the L* (white-black) color axis. Note that topical administration of forskolin caused robust skin darkening in K14-SCF transgenic animals but not in non-transgenic mice. (B) Time course experiment showing darkening of the forskolin-treated ear of K14-SCF extension mice for the indicated times (forskolin-treated ears are indicated by the blue triangles). Vehicle was applied to the right ear for comparison. The L* ± SD results are reported as reflective colorimeter white-black scale, * p ≤ 0.001.
Figure 2-3. Forskolin-induced melanization protects against UV-mediated inflammation as determined by minimal erythematous dose (MED) testing.

(A, B) Position of UV occlusive tape and UVB doses of animals treated twice daily for 5 days. The last topical treatment was applied 48h prior to irradiation. Dorsal skin was exposed to various doses of UVB by using UV-occlusive tape with punched-out 1 cm² circular apertures, and varying exposure times to yield the appropriate dose. After irradiation, circles of exposed skin were labeled with a pen in some experiments. MED’s, defined by erythema and/or edema of the entire circle of exposed skin to a particular dose, were determined 48 hours after exposure. The MED ± SD results are reported as kJ/m² UVB, * p ≤ 0.001.
DISCUSSION

It is vital to select a functional mouse model to study skin melanization. There are differences between human and mice skin such as thickness, epidermal melanocytes, and dermis structure. UV mediates expression of MC1R endogenous ligand α-MSH in keratinocytes. Nevertheless, in Mc1r<sup>e/e</sup> mice, there is no UV-mediated melanization due to MC1R deficiency, and these mice have higher levels of pheomelanin or red/blonde pigment than the dark pigment eumelanin. Similarly, there is no UV- or forskolin- induced pigmentation in K14-SCF non-transgenic mice. In that case, pharmacologic stimulation such as forskolin-mediated cAMP signaling of the adaptive pigmentation pathway provides UV protection for fair-skin mice.

UV sensitivity is a common characteristic in humans unable to tan after long exposure of solar radiation. The deficiency in the production of melanin allows higher dose of UVB to penetrate the skin and induce UV-damage. I hypothesized that the use of forskolin as a short-term treatment allows the accumulation of melanin in Mc1r-deficient mice. I used a mouse model of the fair-skinned individuals and I found that topically applied crude extract of forskolin induced skin darkening by increasing the synthesis of melanin production in the skin. This model mimics the complexion of human skin, retaining epidermal melanocytes compared to non-transgenic mice with dermal melanocytes unable to produce melanin. This was possible by the expression of the stem cell factor K14 at the epidermal basal layer in transgene mice to mimic what occurs in human skin. The location of interfollicular melanocytes is key to obtain an accumulation in melanin. Our laboratory animal model include the K14-SCF transgene on C57BL/6 extension (Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>). Mutated MC1R down-regulates the production of cAMP signaling leading to a pheomelanotic phenotype. However, K14-SCF Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> mice showed an abundant accumulation of protective eumelanin when treated with forskolin. Therefore, the use of a
pharmacologic stimulation of MC1R is able to rescue and balance the production of eumelanin in a fair-skinned background. The mechanism of activation of the MC1R has been well established. MC1R is able to induce cAMP production leading to pro-survival and pro-differentiation signals to melanocytes. However, direct activation of the adenylate cyclase is able to bypass mutations of MC1R signaling. I selected the crude root extract of forskolin as a natural option for a topical treatment against hazardous UV exposure because use of the purified forskolin was not cost-effective for topical treatments. Previous studies from our laboratory showed the use of 40% weight per volume solution of the root extract containing 80uM of forskolin. Here I showed that this dose induces darkening in the skin after the first two applications. I reported that twice-daily application is associated with a clear darkening of the skin providing significant UV protection. Compared to previous studies, our data reports that forskolin can be administrated more than once a day and be tolerated by the mice. There is no swelling of the skin after forskolin is applied. Therefore, the darkening of the skin is due to accumulation of eumelanin and not proliferation of the cells in the epidermis. When topical treatment were discontinued, the dorsal skin gradually returns to its pheomelanotic complexion.

Based on the data, pharmacologic activation of cAMP showed a significant increase in UV-protection as suggested by measuring the minimal erythematous dose (MED). The MED is the lowest dose of UV that induces erythema of the skin. The K14-SCF transgenic extension mice that were treated with forskolin showed > 6 fold increase in MED compared to non-transgenic extension mice. The use of topical stimulation of cAMP rescues melanin synthesis and induces MC1R-dependent signaling providing protection against UV-induced skin injury.

This study has many implications for the prevention of UV-induced skin damage. The skin is constantly exposed to environmental factors, of which solar radiation is a major
carcinogen. Topical pharmacologic activation of MC1R/cAMP provides a possible therapeutic target against individuals unable to tan and who are prone to skin mutagenesis (D’Orazio, Nobuhisa et al. 2006). Forskolin induces darkening of the skin by activating the synthesis of endogenous melanin. The skin will fade back to its baseline skin complexion once the treatment is removed. Therefore, a persistent application is required to maintain darkening of the skin. Forskolin can effectively induce skin darkening and increase UV sensitivity by increasing MED in mice, establishing a proof-of-concept to test the ability of forskolin to rescue deficiencies in the MC1R/cAMP signaling pathway. The study of role of forskolin at the molecular level will provide a mechanism of action to determine how to use this potent drug as a topical treatment.
CHAPTER 3

MC1R signaling pathway increases MnSOD levels in the mitochondria and does not affect mitochondrial oxidative phosphorylation.

INTRODUCTION

This chapter is focused on the regulation of antioxidant defenses in melanocytes. In the skin, melanocytes are located in epidermis and the accumulation of UV-induced damage could lead to melanocyte transformation into melanoma. Antioxidant enzymes are the first line of defense against an increase in ROS. Interestingly, the cell produces endogenous levels of ROS that are able to regulate and to impair cellular signaling pathways. Moreover, mitochondrial production of endogenous levels of ROS in the cell is tightly regulated by antioxidant enzymes.

SODs are the only antioxidant enzymes that are able to interact with a radical and converted it to two different species, $\text{H}_2\text{O}_2$ and $\text{O}_2$. MnSOD is located in the mitochondria and knockdown of this enzyme leads to cell death. It is an essential protein regulated by NF-$\kappa$B. It is not clear what happens once MnSOD engages to superoxide radicals but it is known that it can be inhibited by OONO$^-$ (Kim, Rodriguez et al. 2001). There are limited studies considering the role of MnSOD in the skin (Yan, Li et al. 1999, St Clair, Zhao et al. 2005, Luanpitpong, Chanvorachote et al. 2012, Holley, Xu et al. 2014), especially in melanocytes, the precursor of melanoma.

Preliminary data from our laboratory showed a correlation between the level of MITF and the presence of mtDNA damage in the cell. Different human melanoma cell lines were tested for the expression of MITF (Figure 3-1A). WM1366 and 451Lu were the cell lines with the highest protein levels for MITF and the lowest amount of mtDNA lesions. These lesions were measured by mtDNA amplification after UV exposure (Figure 3-1B). The small and circular mtDNA is more prone to mutation than nuclear DNA (Larsson and
Clayton 1995), Nagley and Wei 1998). A faster amplification of different mtDNA fragments represents a higher frequency of DNA lesions. We found that the use of an oxidative agent such as H2O2 caused increases in mtDNA mutation in cell lines that expressed low levels of MITF (Fig. 3-1B). In addition, there was a decrease in the amount of mutation frequency present in human cell lines after UV exposure with rescue of MC1R/cAMP signaling (Fig. 3-1C, D). The cell lines were treated with chloramphenicol (CAP), an antibiotic whose mechanism of action allows study of mtDNA mutagenesis. CAP binds to mitochondrial ribosomes inhibiting mitochondrial protein synthesis and cellular proliferation. Treating cell lines with sub-lethal doses of UVB allows cells to incorporate mutations that will impair ribosome structure and interfere with CAP binding because of UV-induced DNA mutations to rDNA sequence. If mutations are generated after UV exposure, CAP cannot bind to ribosomes, and cells can grow as a result in its presence. After incubating cells with forskolin as a cAMP activator, the cells were irradiated. The cells that generated mutation on its DNA after UVB exposure were able to proliferate. Forskolin pretreatment decreased mutation frequency from 7 x10^-4 to 3 x10^-4 in A375 cell line (MC1R R151C) and from 6 x10^-4 to 2 x10^-4 in SBCL2 (wild-type MC1R) cells, suggesting that cAMP signaling protects against UV-mediated mitochondrial mutagenesis (Fig. 3-1C, D). We conclude that MC1R signaling has a protective effect against UV-induced mitochondrial mutagenesis.
Figure 3-1. The level of mtDNA damage in melanoma cell lines.

(A) MITF expression in melanoma cells at various stages of progression. Cells were serum starved for 24h and whole cell lysate was probed for MITF levels. (B) H$_2$O$_2$-induced mtDNA damage in a panel of melanoma cells. Cells were serum starved for 24h and then exposed to oxidative stress (100 $\mu$M H$_2$O$_2$) for 30 minutes immediately following damage, DNA was isolated and XL-PCR performed. A 10kb primer set specific to the mitochondrial genome was used to determine levels of mtDNA damage. (C) Chloramphenicol (CAP) resistance assay for wild-type and mutated MC1R. Cells were treated twice to a sub-lethal dose of UV before incubation with CAP growth media for two weeks until cell colonies developed. (D) Representative pictures of colonies. VGP (Vertical growth phase), RGP (Radial growth phase) & MET (Metastatic phase)

Experiment performed in collaboration with Dr. Stuart Jarrett, PhD.
In this chapter, I studied the role of the rescue of MC1R pathway to enhance the expression of several genes that have a role in the oxidative stress regulation. Several studies confirmed that MITF plays a role in skin other than by inducing melanin production (Kim, Kim et al. 2005, Carreira, Goodall et al. 2006, Liu, Fu et al. 2009, Yi, Zhao et al. 2011, Berwick, MacArthur et al. 2014). Nonetheless, there is limited evidence of specific induction of the gene expression of antioxidant enzymes after activation of MITF in melanocytes.

In addition, I studied activation of MC1R signaling and its role in the translocation of the antioxidant enzyme MnSOD. I hypothesized that MC1R/cAMP increases the gene expression of MnSOD. I tested the role of MC1R in the induction of MnSOD protein levels and activity. Lastly, I explored the role of the MC1R in mitochondria metabolism as a potential functional effect of MC1R pathway. The MC1R/cAMP might be a potential target for the induction of antioxidant defenses after exposure to solar UV.

SPECIFIC AIM:
To study the role of MC1R in antioxidant defenses and mitochondrial oxidative phosphorylation.

a) To explore the expression of oxidative stress related genes after pharmacologic induction of the MC1R pathway.

b) To study a mechanism of levels/activity of MnSOD after activation of the MC1R/cAMP signaling pathway.

c) To examine the role of MC1R/cAMP in mitochondria metabolism.

METHODS AND MATERIALS

CELL LINES AND PLASMIDS

A375, SKMel2 and HEK293 cell lines were purchased from ATCC. pcDNA3.1/MnSOD (human) 3’-FLAG-MnSOD was provided by Dr. Jian-Jian Li from the University of
California Davis. WT MC1R and mutated MC1R R160W were constructed with the Quick Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA.). Mouse primary melanocytes were isolated from C57BL/6 extension K14-SCF transgenic extension.

REAGENTS
The following antibodies were purchased commercially: SOD2 (1H6; western blot) (Pierce-Thermo Scientific, Waltham, MA.); GSR and GPX antibodies (Santa Cruz Biotechnology, Santa Cruz, CA.); GAPDH (Life Technologies, Grand Island, NY); VDAC, HSP70, FLAG (DKDDDDK), PKA P/S antibodies (Cell Signaling, Boston, MA.); HRP-conjugated secondary antibodies (Abcam, Cambridge, MA.) SOD determination kit (Sigma-Aldrich, St. Louis, MO.) and the Seahorse Analysis reagents (Seahorse Bioscience Massachusetts, USA.)

ISOLATION OF PRIMARY MELANOCYTES
The protocol used was published from our laboratory from the article of Scott and colleagues (Scott, Wakamatsu et al. 2009). The primary murine cells were obtained from Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> C57BL/6J animals unless otherwise stated. Melanocytes were selected for and grown in a Ham’s F12 media and established normal murine keratinocyte conditioned media mixture.

mRNA ISOLATION FROM TISSUE SAMPLES
Skin biopsies were taken at indicated time-points. Skin tissues were ground in liquid nitrogen with a mortal and pestle. The skin was homogenized with Trizol® reagent following manufacturer protocol. The mRNA was processed using the RNAeasy kit (Qiagen, Valencia, CA.) following manufacturer’s instruction. mRNA was quantified, normalized and converted to cDNA using the iScript cDNA kit (Qiagen, Valencia, CA.).
qPCR
The cells were plated in 35mm dishes and with 10µM forskolin or 0.1% ETOH. Untreated cells served as control samples. The cells were dissociated by treatment with 0.25% trypsin/EDTA at 37°C for 5 min. The cells were harvested, centrifuged and RNA was isolated using the RNAeasy kit (Qiagen, Valencia, CA.). RNA was converted to cDNA using the iScript cDNA kit (Qiagen, Valencia, CA.). The cDNA from mouse tissue was used to perform quantitative PCR assay by the LifeCycle Real-time PCR (Roche, Indianapolis, IN) with the β-actin as a reference gene included for each reaction. The levels of expression of genes in stimulated cells were compared with the untreated control groups. The cDNA from human melanocytes was used to perform quantitative PCR assay by the CF-96 Biorad qPCR with the 18S as a reference gene included for each reaction. The levels of expression of genes in stimulated cells were compared with the untreated control groups.

XL-PCR
Genomic DNA was extracted using a commercially available Qiagen genomic-tip kit (Qiagen, Inc., CA). The quantitative polymerase chain reaction (qPCR) assay measures the average oxidative lesion frequency on mtDNA. DNA damage was quantified by comparing the relative efficiency of the amplification of a 13.4kb mtDNA gene fragment and normalized to 250bp fragment (this small fragment has a statistically negligible chance of sustaining oxidative stress-induced base damage). PCR conditions used in this study were based on previously reported sequences for mtDNA primers (Ayala-Torres, Chen et al. 2000, Jarrett and Boulton 2005). qPCR was carried out on a DNA Engine thermal cycler with all reactions being a total volume of 100μl containing 15ng of total genomic DNA, 1unit of XL rTth polymerase, 3.3 XL PCR buffer II (containing potassium acetate, glycerol and DMSO) and final concentrations of 200μM dNTP’s, 1.2mM Mg(OAc)\textsubscript{2} and
0.1μM primers. The gene fragments were amplified using the following thermo-cycling profile: The PCR was initiated with the addition of the 1 unit of XL rTth polymerase when samples had reached a temperature of 75°C. This was followed by an initial penetration for 1 min at 94°C, cycles of denaturation at 94°C for 30s and primer extension at 60°C for 13 min. After the PCR cycles had been completed, a final extension at 72°C for 10 min was performed. The nuclear and mitochondrial gene products underwent 28 cycles and 26 cycles of thermo-cycling, respectively. After the completion of the qPCR, the gene products were resolved on a 1% agarose gel and digitally photographed on a UV transilluminator (UVi Tec, UK). The intensity of the PCR product bands was quantified with Scion Image analysis software (Scion Corporation, Version Beta 4.0.2).

CHLORAMPHENICOL RESISTANCE ASSAY
Chloramphenicol (CAP)-resistance was measured as a measurement of mtDNA mutagenesis. A375 cells were seeded onto 6-well dishes at 500 cells/well. After the 24 hours of incubation, the growth medium was replaced with medium containing 10uM Forskolin and incubate for 24 hrs. The cells were irradiated at a sub-lethal dose of UVB (5J) and incubate for 24 hours. If the experiment responded to a schedule of treatments, step 2 is repeated before each irradiation. At the end of all treatments, the cells were incubated with growth medium containing 1mM CAP. The cultures were maintained until colonies visible to the naked eye were formed; the colonies were then fixed with methanol and stained with 0.5% crystal violet in 50% methanol (roughly takes 2 weeks). The mutation frequency is calculated by dividing the existing colonies by the amount of cells plated.

WESTERN BLOT, IMMUNO-PRECIPITATION AND ACTIVITY ASSAY
Cell lines were lysed in RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and 1X Halt Protease and Phosphatase Inhibitor
Cocktail, EDTA-Free (Thermo Scientific, Waltham, MA.)). Total protein was quantified using Pierce BCA protein assay (Thermo Scientific, Waltham, MA.). The amount of protein per sample was normalized and loaded onto SDS-PAGE gels. Immunoblotting was performed using antibody manufacturer protocols. Immuno-precipitations were performed with equal amount of total protein incubated overnight at 4°C with 5μg of antibody and protein G agarose, washed three times with RIPA buffer, and separated by SDS-PAGE prior to immunoblotting. For indicated experiments the SDS-PAGE gel was stained with Colloidal blue. Several bands were selected for their identification at the Proteomic facility of the University of Kentucky. All immunoblotting was performed with enhanced chemiluminescence (ECL) and quantified with the STORM system. Bands were quantified using Image J (NIH, Bethesda, MA.). Equal mitochondrial and whole cell protein were used for the SOD determination assays, and the assay was performed as previously described (MacMillan-Crow, Crow et al. 1996) and following manufacture’s protocol (Cayman Chemical Co. Ann Harbor, MI.). Potassium cyanide (KCN) 1mM solution was used as an inhibitor of Cu/ZnSOD and ECSOD at indicated experiments.

MITOCHONDRIA ISOLATION

The cells were plated in 150mm dishes and treated for cAMP stimulation. Treatments included 10μM forskolin or 0.1% vehicle control and untreated cells as the control samples. The cells were dissociated by treatment with 0.25% trypsin/EDTA at 37°C for 5 min. The cells were harvested, centrifuged and mitochondria were isolated using a buffer containing 10mM NaCl, 1.5mM MgCl₂, 10mN Tris-HCl, pH 7.5. Cells were homogenized on ice and centrifuged. The sucrose gradient was prepared with a 2M sucrose solution in 10mM Tris-HCl and 1mM EDTA (TE buffer) following indicated dilutions. Pelleted material was layered on a 1:1 mixture of 1.7M sucrose and 1.0M sucrose and centrifuged at 24,000 rpm for 40 min. The fraction containing mitochondria was washed in TE buffer and
centrifuged for 10 min at 13,000 rpm. The pellet (mitochondria) was re-suspended in 250nM sucrose. The solution was diluted in RIPA buffer.

**TRANSFECTION FLAG-TAGGED MnSOD PLASMID**

Designated cell lines were plated in 35mm dishes and transfected with 3'-FLAG-MnSOD, pcDNA3.1, MC1R<sup>E/E</sup> and MC1R<sup>R160W</sup> using Effectene Transfection Reagent (Qiagen, Valencia, CA.) according to manufacturer protocol.

**PROTEIN KINASE ASSAY**

PKA kinase assays were initiated by incubating 10nM recombinant catalytic subunit of PKA enzyme (Invitrogen, Grand Island, NY.) and HA-tagged MnSOD (Fitzgerald, Acton, MA.) at 30°C for 10 min, in 40mM Tris-Cl (pH 7.5), 10mM MgCl<sub>2</sub>, 1mM DTT, 100μg/ml BSA, and 10μM ATP. The reaction was stopped by the addition of 10μl of 100mM EDTA. The extent of PKA phosphorylation was measured by immune-blot with anti-phosphoserine (Abcam Cambridge, MA.). HA-tagged MnSOD was immunoprecipitated with anti-HA overnight at 4°C and protein G agarose, washed five times with RIPA buffer, and separated by SDS-PAGE prior to immunoblotting. All immunoblotting was performed with enhanced chemiluminescence (ECL) and quantified with the STORM system.

**SEAHORSE ANALYSIS**

Seahorse analysis experiments were performed after cAMP stimulation for 1, 3, 6 and 24 hours with 10μM forskolin or 0.1% ETOH before exposure to UVB consisting of two Westinghouse F15T8UV-B lamps at 500, 1000, 1500 and 5000 J/cm<sup>2</sup>. Oxygen-consumption rates (OCR) was analyzed at the University of Kentucky Free Radical Biology and Cancer Shared Facility. OCR was controlled at all times during the experiment to exclude any pathway independent effect. Fccp, an uncoupling agent, was used to accelerate the electron transport chain (ETC), and doses were optimized together with amount of cells per experiment. Then, the Seahorse system measured the OCR (pmol).
and what impact cAMP stimulation has on oxidative phosphorylation. The OCR was measured in triplicate during maximal respiration controlled by fccp and in the presence of rotenone as an ETC inhibitor. Values were normalized to the protein concentration per sample, and OCR levels were compared between untreated vs cAMP-stimulated conditions.

**STATISTICAL ANALYSIS**

The data was analyzed between cohorts of replicate samples (n = 3) by one way ANOVA using the Bonferroni post-test (Graph Pad PRISM software). p values <0.05 were considered statistically significant.

**RESULTS**

**MC1R INCREASES EXPRESSION OF ANTIOXIDANT ENZYMES AT THE TRANSCRIPTION LEVEL.**

I explored the role of the MC1R as a regulator of the gene expression of several antioxidant enzymes. Although MC1R pathway has been well described as a potent regulator of melanin production and skin pigmentation, there are limited studies looking at its role in the expression of antioxidant enzymes in the skin. Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> extension mice were used (the same mice that showed rescue of melanin synthesis after forskolin treatment). I performed a kinetic experiment measuring mRNA expression of MnSOD, CAT, GPX and Nfe2l1 or NRF2 (Figure 3-2). There was a 2.5-fold increase for the expression of SOD2 after 6 hours of topical forskolin treatment. Gene expression of MITF was used as an internal control for the experiment. There was no significant difference for other antioxidant enzymes compared to the 0 hour time-point. An important caveat to consider was that mRNA was isolated from whole skin samples (dermis and epidermis) from which melanocytes constitute roughly 10 percent of the cells present. Since MC1R is located in the plasma membrane of melanocytes, I isolated primary melanocytes from Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> mice. I tested the expression of MITF in these primary cells and there was
an increase in MITF gene expression 3, 6 and 24 hours after forskolin treatment (Figure 3-3A). α-MSH was included in this experiment as a negative control in these MC1R-defective cells, and there was no induction of MITF after α-MSH treatment. Gene expression of SOD2 nor NFE2I2 (NRF2) increased after FSK treatment, suggesting that perhaps SOD2 and NRF2 are not target of the transcription factor MITF in mouse melanocytes. Then, human melanoma cell lines with mutated MC1R R151C were tested for the expression of MITF after forskolin treatment in several time points (Figure 3-3B). There was an increase of MITF expression in a time dependent matter with the higher expression at 6 hours. I selected the 6 hour time point to analyze a gene array that included antioxidant enzymes, several transcription factors and other protein regulators by qPCR. An oxidative stress panel for 60 genes was tested in response to MC1R activation. Out of the genes tested, 22 showed a positive response (at least two-fold increase). Of these, FOXO1, BCL2, JUN, MAPK1, 3 &9, STAT1, HSPD1 & DDIT3 were induced. These genes are known to have a role in the regulation of apoptosis. The TLR4 is a Toll-like receptor was increased together with the inflammatory cytokine IL1B. The activation of the adaptive immune system is considered a protective effect in the skin since it promotes healing in the skin after UV-induced sunburn (Greene, Hoover et al. 1978). Moreover, there was an increase in the expression of the antioxidant enzymes SOD1, GPX1, & 3, Nrf2 and NF-κB. Both Nrf2 and NF-κB were upregulated to a 6 and 4-fold increase, respectively. RELA is a subunit of NF-κB and its expression was increase as well. Interestingly, some downstream targets of Nrf2 and NF-κB did not show a significant effect after MC1R activation by forskolin in human melanocytes. For example SOD1, 2 & 3 were down-regulated and they are known to be activated by NF-κB. Nrf2 regulates the expression of GSTP1 and GCLC. Both are involved in the glutathione pathway and their gene expression after the 6-hour time point was down regulated. Additional kinetics experiments are require to address the effect on MC1R on these genes. There was no
increase in the expression of several antioxidant enzymes (CAT, TP53, MDM2 among other genes relative to the expression of GAPDH) (Table 3-1), but there were significant increases in the expression of PRDX3 and MAPK9 (Table 3-1). Although some genes were down regulated, MC1R activation had a role in the up-regulation of several regulators of antioxidant enzymes and oxidative stress related genes at the transcriptional level.

**MC1R INCREASES MnSOD PROTEIN LEVELS IN MITOCHONDRIA AT EARLY TIME POINTS.**

I wanted to study the role of MC1R in the protein levels of MnSOD in melanocytes. There was no significant increase in the protein levels of MnSOD (Figure 3-4A), from 1 to 24 hours after cAMP stimulation in whole cell lysate. The protein levels of GSR and GPX (Figure 3-4B) did not increase after a treatment of 6 hours. However, there was an increase in the protein levels of MnSOD in mitochondria lysate at early time points (Figure 3-4C, D). Furthermore, there was an increase in MnSOD protein levels after cAMP stimulation plus 50J UVB or 50uM of H₂O₂ in mitochondria isolated from MC1R R151C melanocytes (Figure 3-5) after 1 hour of forskolin treatment. I transfected human embryonic kidney cells (HEK293) with wild-type and mutated MC1R to test for the protein levels of MnSOD. There was a significant increase in the levels of MnSOD in MC1R R160W with forskolin (Figure 3-6). However, HEK 293 transfected with wild-type MC1R showed no induction of the protein levels of MnSOD. These results at early time points suggesting that the up-regulation of MnSOD protein levels may not involve transcriptional up-regulation but rather MnSOD transport and/or stability.

**MC1R SIGNALING INCREASES MnSOD INTERACTION WITH CHAPERONE PROTEIN HSP70.**

To investigate the possibility that cAMP-mediated increases in MnSOD were regulated by binding partners, I made used of FLAG tagged-MnSOD constructs obtained from Dr. Jian-Jian Li from the Comprehensive Cancer Center at UC Davis. I tested MC1R R151C cells after 10uM forskolin and 50uM H₂O₂ treatment for 1 hour. Cellular lysates were
immunoprecipitated for FLAG and analyzed by western blot. The SDS-PAGE gel was stained with colloidal blue and treatments were compared. The bands that increased or decreased by forskolin treatment were selected and removed for the gel to be sent for analysis. A band close to the 70 kDa size was sent for identification with the proteomic facility (Figure 3-7A). They identified it to be heat shock protein 70 (HSP70) increased in associated with FLAG-tagged MnSOD after forskolin treatment. I tested the cell line with forskolin followed by 30 minutes of hydrogen peroxide and found an increase in the interaction of HSP70 with FLAG after treatment with forskolin (Figure 3-7B, C). HSP70 was also increase in the western blot for whole protein without IP. However, when the cells were treated with H₂O₂ the whole cell increase of HSP70 did not change. But, the interaction remained in the IP FLAG-tagged MnSOD after H₂O₂ treatment. HSP70 is a chaperone protein that is found in the cytoplasm. As a chaperone, it has a role of transporting proteins around the cell and HSP70 is linked to translocation of glutathione to the mitochondria (Guo, Wharton et al. 2007).

MnSOD INTERACTION WITH HSP70 IS PKA DEPENDENT.

I wanted to test if PKA had a role in the increase of HSP70 interacting with FLAG tagged-MnSOD. I tested the inhibitor H89 that blocks the PKA catalytic subunit (Figure 3-8A). I treated FLAG tagged-MnSOD A375 (MC1R R151C) cell line for one hour with H89. Then, the cells were treated with 0.1% ETOH and 10uM forskolin for 1 hour. I saw a decrease in the interaction between HSP70 and FLAG. I tested doses of H₂O₂ and chose 50uM for 30 minutes (Figure 3-8B). I observed no increase in HSP70 after I.P. with FLAG after adding H89. The protein sequence of MnSOD identified two possible PKA phosphorylation sites potentially explaining cAMP-enhanced interactions with HSP70. These sites could be used as target in future studies for site-directed mutagenesis to continue further studies about HSP70 interaction with MnSOD.
FORSKOLIN RESCUE OF MC1R SIGNALING INCREASES MnSOD ACTIVITY.

I wanted to investigate whether the protein levels of MnSOD and its interaction with HSP70 might result in an increase in MnSOD protein activity. I tested whether cAMP affects the activity of MnSOD using the Superoxide Dismutase Assay Kit (Cayman Chemical Co., Ann Harbor, MI). Total protein (whole cell) was isolated from MC1R R151C cell lines. Efficacy of superoxide removal using xanthine oxidase as a standard for ROS production (Figure 3-9) was quantified. There was an increase in the levels of superoxide dismutase activity after 1 and 3 hours of forskolin treatment in whole cell lysate (Figure 3-9A). These results include the activity of Cu/ZnSOD, MnSOD and ECSOD. Potassium cyanide (KCN) was added to the protein solution to inhibit the activity of Cu/ZnSOD and ECSOD. The inhibition of Cu/ZnSOD and ECSOD enable the detection of MnSOD activity exclusively. Figure 3-9A shows no significant difference in MnSOD activity between each time point in whole cell protein lysate. The concentration of xanthine oxidase was decreased within minutes of the reaction and there was no difference between forskolin and vehicle. However, whole cell lysate treated with KCN showed a significant decrease in the presence of forskolin. Interestingly, there was an increase in MnSOD activity (U/mg) at the one hour time point (Figure 3-9B). Then, mitochondria protein lysate was tested together with potassium cyanide to measure MnSOD activity. Similarly, there was an increase at the one hour time point after forskolin treatment. Therefore, I concluded that the activation of MC1R/cAMP signaling increased MnSOD activity at early time points.

MC1R SIGNALING DOES NOT AFFECT MITOCHONDRIA METABOLISM.

MnSOD is an antioxidant enzyme located in the mitochondria. I wanted to investigate if there was any effect in mitochondria metabolism after forskolin treatment. Seahorse analysis was optimized to test the oxygen consumption rate (OCR) after stimulation of cAMP in MC1R R151C cells (Figure 3-10). I tested the effects of one hour treatment in
order to compare the results with the protein levels and immune-precipitation assay. The results are shown as OCR percentage (A) and OCR concentration at pMol/min. There was no increase in the OCR after cAMP stimulation at the basal metabolism, ATP production or maximal respiration. I included a dose of UVB irradiation of 50J to test effect UV as a positive control and investigated a possible protective effect after forskolin treatment. There was no significant difference between forskolin plus UVB and UVB alone within the same phase of mitochondria metabolism. However, there was a significant difference in the levels of maximal respiration comparing forskolin plus UVB with UVB alone.
Figure 3-2. MITF and SOD2 gene expression were rescued after forskolin treatment in whole skin tissue.

Mc1r $^{e/e}$ Tyr $^{+/-}$ were treated with 40% w/v forskolin and vehicle control (70% ETOH, 30% PG) for 1 to 6 hours. Skin biopsies were taken and mRNA was isolated and analyzed by qPCR using primers specific for mouse mRNA. The gene amplification was normalized to 18S and the relative amplification levels at all-time points after forskolin and vehicle treatment were normalized to 0 hours control.
Figure 3-3. MITF gene expression was rescued after forskolin treatment.

(A) Mc1r e/e Tyr +/+ primary melanocytes were treated with 10uM Forskolin and 0.1% ETOH for 3 to 24 hours. mRNA was isolated using RNAeasy kit (Qiagen). The samples were analyzed by qPCR using primer specific for mouse mRNA. (B) Human melanocytes MC1R R151C were treated with 10uM Forskolin and 0.1% ETOH for 0.5 to 6 hours. mRNA was isolated and analyzed with qPCR using primer specific for human mRNA. The gene amplification was normalized to 18S (A) or GAPDH (B) and the relative amplification levels at all time-points after forskolin and vehicle treatment were normalized to 0 hours control.
## Table 3-1. Antioxidant enzymes gene array expression after forskolin treatment.

Human melanocytes (MC1R R151C) were treated with 10uM Forskolin and 0.1% ETOH for 6 hours. mRNA was isolated and analyzed with Primer PCR Assay for oxidative stress pathway (Biorad, Hercules CA.) using primer specific for human mRNA. The gene amplification was normalized to GAPDH and the relative amplification levels after forskolin treatment were normalized to vehicle control (0.1% ETOH).

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Fold change</th>
<th>Gene name</th>
<th>Fold change</th>
<th>Gene name</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>1.000</td>
<td>PARK2</td>
<td>1.005</td>
<td>SOD2</td>
<td>0.588</td>
</tr>
<tr>
<td>GPX3</td>
<td>7.945</td>
<td>SOD1</td>
<td>1.705</td>
<td>LCN2</td>
<td>0.547</td>
</tr>
<tr>
<td>FOXO1</td>
<td>6.589</td>
<td>JAK2</td>
<td>1.659</td>
<td>SHC1</td>
<td>0.547</td>
</tr>
<tr>
<td>BCL2</td>
<td>6.320</td>
<td>APP</td>
<td>1.591</td>
<td>GCLM</td>
<td>0.521</td>
</tr>
<tr>
<td>NFE2L2</td>
<td>5.938</td>
<td>CYP2E1</td>
<td>1.464</td>
<td>PRDX1</td>
<td>0.497</td>
</tr>
<tr>
<td>STAT1</td>
<td>5.696</td>
<td>PRK2</td>
<td>1.454</td>
<td>SERPINE1</td>
<td>0.451</td>
</tr>
<tr>
<td>MAPK1</td>
<td>5.352</td>
<td>CAT</td>
<td>1.434</td>
<td>DHCR24</td>
<td>0.444</td>
</tr>
<tr>
<td>NFkB1</td>
<td>4.659</td>
<td>GLRX2</td>
<td>1.424</td>
<td>TP53</td>
<td>0.429</td>
</tr>
<tr>
<td>GPX1</td>
<td>4.563</td>
<td>MDM2</td>
<td>1.395</td>
<td>G6PD</td>
<td>0.412</td>
</tr>
<tr>
<td>LDHA</td>
<td>4.000</td>
<td>PRDX5</td>
<td>1.396</td>
<td>PRDX4</td>
<td>0.376</td>
</tr>
<tr>
<td>JUN</td>
<td>4.347</td>
<td>GPX4</td>
<td>1.266</td>
<td>GCLC</td>
<td>0.361</td>
</tr>
<tr>
<td>MAPK8</td>
<td>4.028</td>
<td>GSR</td>
<td>1.157</td>
<td>NQO1</td>
<td>0.275</td>
</tr>
<tr>
<td>PRDX3</td>
<td>3.918</td>
<td>PCN2</td>
<td>1.157</td>
<td>EGFR</td>
<td>0.268</td>
</tr>
<tr>
<td>RELA</td>
<td>3.160</td>
<td>PTGS2</td>
<td>1.149</td>
<td>AC0038.1</td>
<td>0.245</td>
</tr>
<tr>
<td>DDIT3</td>
<td>2.990</td>
<td>AKT1</td>
<td>1.000</td>
<td>PRDX6</td>
<td>0.187</td>
</tr>
<tr>
<td>HSPD1</td>
<td>2.868</td>
<td>TXNRD1</td>
<td>1.000</td>
<td>APEX1</td>
<td>0.150</td>
</tr>
<tr>
<td>TLR4</td>
<td>2.657</td>
<td>HPRT1</td>
<td>0.807</td>
<td>PRDX2</td>
<td>0.115</td>
</tr>
<tr>
<td>MAPK9</td>
<td>2.144</td>
<td>G3TP1</td>
<td>0.801</td>
<td>HMOX1</td>
<td>0.103</td>
</tr>
<tr>
<td>PRKCD</td>
<td>2.114</td>
<td>OGG1</td>
<td>0.737</td>
<td>APOA1</td>
<td>0.100</td>
</tr>
<tr>
<td>MIF</td>
<td>2.085</td>
<td>CASP3</td>
<td>0.717</td>
<td>CD36</td>
<td>0.100</td>
</tr>
<tr>
<td>SIRT1</td>
<td>2.071</td>
<td>PRKCA</td>
<td>0.683</td>
<td>IL6</td>
<td>0.100</td>
</tr>
<tr>
<td>IL1B</td>
<td>2.028</td>
<td>MAP3K5</td>
<td>0.678</td>
<td>PRKCB</td>
<td>0.100</td>
</tr>
<tr>
<td>SRC</td>
<td>2.014</td>
<td>ADIPOQ</td>
<td>0.646</td>
<td>CYBA</td>
<td>0.035</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CLU</td>
<td>0.646</td>
<td>SOD3</td>
<td>0.000</td>
</tr>
</tbody>
</table>
Figure 3-4. MnSOD protein expression did not change after forskolin treatment in whole cell lysates but did increase in mitochondria.

Human melanocytes MC1R R151C were treated with 10uM Forskolin and 0.1% ETOH for 30 minutes to 24 hours. Whole cell (A, B) and mitochondria (C, D) protein was isolated and quantified to be examined by western blot. (B) The cells were treated for 6 hours with or without 50uM H2O2. (C) The cells were treated for 30 min. with 10uM forskolin and 50J of UVB. (D) The cells were treated for different time-points with 10uM forskolin and 0.1% ETOH. The relative expression of MnSOD (relative to loading control GAPDH (cytoplasm) or VDAC (mitochondria)) was graphed after forskolin treatments were normalized to initial time-point.

Panel C was performed by Dr. Stuart Jarrett, PhD.
Figure 3-5. MnSOD protein expression increased after forskolin treatment in mitochondria.

Human melanocytes MC1R R151C were treated with 10uM Forskolin, 0.1% ETOH for 1 hour, 50 J UVB and 50uM H2O2. Mitochondria protein was isolated using sucrose gradient and quantified to be examined by western blot. The relative MnSOD expression (relative to loading control VDAC) was graphed after forskolin treatment were normalized to vehicle control.
Figure 3-6. The role of mutated and wild-type MC1R signaling role in the expression of MnSOD.

HEK 293 were transfected with wild-type MC1R and R160W. The transfected cells were treated for 1 hour with 10μM forskolin. Whole cell lysates were isolated, quantified by western blot against indicated-proteins.
Figure 3-7. HSP70 binds to MnSOD after MC1R activation.

(A) Human melanoma MC1R R151C cell line were treated for 1 hour with 10uM forskolin or 0.1%ETOH and protein was isolated and IP of FLAG tagged-MnSOD was performed. Colloidal blue stain was performed and the indicated band was sent for proteomic identification. (B) Human melanoma MC1R R151C cell line transfected with FLAG tagged-MnSOD. Then, (C) the cells were treated with 0.1%ETOH and 10uM forskolin from 1 hour. 50uM H$_2$O$_2$ was added to the indicated samples for 30 min. Protein was isolated and IP of FLAG tagged-MnSOD was perform followed by a western blot for HSP70. (C) Whole cell protein (without IP) was included and a western blot was performed for the loading control FLAG.
Figure 3-8. FLAG-tagged MnSOD binding to HSP70 is PKA dependent.

(A) Human melanoma MC1R R151C cell line transfected with FLAG tagged-MnSOD treated with 10uM H89 for 1 hour. Then the cells were treated with 0.1% ETOH, 10uM Forskolin for an additional 1 hour. 50uM H_{2}O_{2} was added to the indicated samples for 30 min. Protein was isolated and IP of FLAG tagged-MnSOD was perform followed by a western blot for HSP70. Input protein (without IP) was included and a western blot was performed for loading control FLAG or MnSOD.

(B) The PKA kinase assay was performed using recombinant protein HA-MnSOD and PKA. Both were mixed for 10 minutes and HA-MnSOD was IP and separated in a SDS-PAGE. Immunoblotting was performed for p-serine.

Panel B was performed by Dr. Stuart Jarrett, PhD.
Figure 3-9. MnSOD protein activity does not change after forskolin treatment.
Human $MC1R^{R151C}$ melanocytes were treated with 10uM Forskolin and 0.1% ETOH for 1 to 3 hours. (A) Whole cell protein, (B) whole cell protein plus 1mM potassium cyanide (KCN) (C) and mitochondria protein plus KCN were isolated and quantified to be examined by SOD activity assay (Cayman Chemical Co., Ann Harbor, MI.). The activity of SOD in U/mg was graphed relative to 0 hour control sample. GAPDH was the loading control for whole cell lysate and VDAC for mitochondria lysate. * p < 0.01
Figure 3-10. MC1R signaling did not affect mitochondria metabolism.

(A) The percentage and (B) pmol/min concentration of the oxygen consumption rate (OCR) were measured using the Seahorse Analysis. Human melanocytes MC1R R151C were treated with 10uM Forskolin, 0.1% ETOH for 1 hour, and 50J UVB. After initial treatments, the cells were treated with Oligomycin A, an inhibitor of ATP synthase. FCCP, uncoupled respiration, measures ETC integrity, functionality, and capacity. AA/Rotenone inhibits mitochondria NADPH dehydrogenase/complex 1 to test for the pathway of mitochondria metabolism using the Seahorse analysis. The OCR was quantified per each treatment. The OCR ± SD results are reported as pmol/min, * p ≤ 0.05 ** p ≤ 0.01.
DISCUSSION

In this chapter, I hypothesized that MC1R signaling pathway regulates the expression of antioxidant enzymes. The gene expression in whole skin samples might be different than purified melanocytes since the skin harbors many different types of cells. Forskolin is able to rescue MC1R signaling in-vivo, therefore, I took skin biopsies of the Mc1<sup>e/e</sup> Tyr<sup>+/+</sup> mice treated at different time points with forskolin. There was an increase of 2.5 fold of SOD2 gene expression in the skin samples. However, SOD2 did not show an increase after isolating primary melanocytes from Mc1<sup>e/e</sup> Tyr<sup>+/+</sup> mice. The presence of other cell lines in the skin might have a role in the up-regulation of SOD2. It is known that NF-κB is involved in the immune system and mediates the transcription of SOD2. It is possible that when melanocytes are isolated from the skin, they lose the interactions with specific cell types that promote gene expression of SOD in the skin.

Here, I report a protective role of MC1R in the expression of transcription factors, post-translational regulators and proteins that are part of the oxidative stress pathway. The 6 hour time point had its higher expression of the transcription factor MITF, a downstream target of MC1R pathway. Interestingly, genes involved in the base excision repair pathway such as OGG1 and APEX1 showed no increase at the gene expression. However, there was a significant increase in the expression of NF-κB, which regulated the expression of SODs, and an increase in Nrf2 that regulates the expression of glutathione and glutathione regulating proteins such as GPX1 and GPX3. A 6 hour time point provides limited information about the mechanism of action by which MC1R increases the protein levels of these enzymes. However, in support of our hypothesis, it is clear that several antioxidant enzymes may be up-regulated at the gene level after forskolin induced MC1R signaling rescue.

SOD2 was not increased after cAMP production in human melanoma cell line compared to results in mouse melanocytes. Therefore, I hypothesized that there might be
up-regulation MnSOD at protein levels in MC1R-deficient human melanocytes after forskolin treatment. Remarkably, MC1R pathway regulated the protein levels of MnSOD in mitochondria, suggesting a role at the post-translation level since an early time point (30 minutes) seems inadequate for a transcriptional effect. However, there was a decrease in the level of GSR and GPX protein levels after the addition of H₂O₂. This is not surprising since GSR and GPX are the first line of antioxidant defense after oxidative injury. A decrease in their protein levels leads to the activation of other antioxidant enzymes and their regulators. MnSOD is only expressed in the mitochondria, perhaps explaining why I was not able to observe cAMP-induced differences in whole cell lysate from human melanocytes. Rather, protein levels of MnSOD were increased only when mitochondria lysate was isolated.

The transfection of wild-type MC1R in HEK293 cells showed a slight decrease in the protein levels of MnSOD after MC1R activation with forskolin. Since HEK293 cell line is not skin specific, it is possible that MnSOD protein levels are regulated differently than in native melanocytes. One option to clarify this issue would be to inhibit the expression of MC1R with siRNA in human melanocytes and test for the protein levels of MnSOD before and after forskolin treatment. Other possibilities to explain high levels of MnSOD in unstimulated MC1R wild-type melanocytes include ligand-independent MC1R signaling or altered number of MC1R proteins expressed in the plasma membrane. HSP70 is known to have a role in the translocation of glutathione to the mitochondria (Guo, Wharton et al. 2007). Surprisingly, this protein interacts with MnSOD after the activation of MC1R signaling plus H₂O₂. MC1R deficient human melanocytes that were treated with forskolin that showed a 3.7 fold increase in MnSOD-associated HSP70 protein levels. However, there was no difference once H₂O₂ was added to the cells. Interestingly, immune-precipitation experiments using FLAG-tagged MnSOD showed an interaction between MnSOD and HSP70 after forskolin treatment and forskolin plus H₂O₂. This means that the
MC1R signaling enhancing the interaction of MnSOD with HSP70 might have a role in the translocation of MnSOD to the mitochondria. This interaction was lost after adding a PKA inhibitor. This suggests that the mechanism of this interaction was PKA dependent. Based in the results on the protein kinase assay, there may be phosphorylation of MnSOD by PKA at any serine in MnSOD sequence. However, PKA might also have a role in the regulation of HSP70 as a transporter of MnSOD. Further experiments with recombinant protein might help to decipher a mechanism. Future experiments would focus on the identification of specific phosphorylation site(s), mutating them and determining effects on interactions between MnSOD and HSP70. The study of a possible phosphorylation of MnSOD increasing its interaction with the chaperone protein HSP70 is a potentially interesting discovery. However, it is important to consider that the regulation of the phosphorylation network in the cell requires both kinases and phosphatases and therefore may be more complex than one single post-translational modification. Although we focused on PKA since it is a target of cAMP, there are phosphatases that might be target of cAMP such as protein phosphatase 2A (PPA) which is inhibited by cAMP (Dodge-Kafka, Bauman et al. 2010) and opens an interesting mechanism of phosphatase regulation by cAMP that might be relevant in melanocytes.

I hypothesized that the activity of MnSOD was up-regulated after forskolin treatment in MC1R deficient human cell lines. There was an increase in the removal of superoxide radical generated by xanthine oxidase after forskolin induced MC1R signaling in MC1R deficient human melanocytes. These data are consistent with the increase in the expression of MnSOD in mitochondria after 1 hour of forskolin treatment. Based on these results, I showed for the first time that MC1R signaling might have a potential role in the up-regulation of MnSOD activity at early time points.

Moreover, there is a significant increase in maximal respiration comparing UVB treated cells with UVB plus forskolin-induced MC1R. UVB alone produces a significant
decrease in maximal respiration and forskolin seems to rescue that decrease. The analysis of mitochondria phosphorylation is challenging in epidermal melanocytes. This cell type contains lower levels of mitochondria compared with a muscle cell. Therefore, the values of this assay were lower than expected at normal rate of mitochondrial phosphorylation. Nonetheless, based in these results, there is a possible rescue in maximal respiration after forskolin treatment with or without UVB.

In this chapter, I demonstrated the role of MC1R/cAMP provides protection against DNA mutagenesis. In addition, MC1R enhances MnSOD levels/activity in mitochondria and does not affect the mitochondria metabolism as a potential functional effect of the pathway. MC1R signaling is a potential target for the prevention of UV-induced oxidative damage in the skin.
SUMMARY

Pharmacologic activation of the MC1R signaling pathway protects the skin against UV-induced damage and promotes the activity of the antioxidant enzyme MnSOD. Individuals with deficiencies in the MC1R signaling pathway can benefit from pharmacologically-induce melanin production and rescue of MC1R signaling. Dark melanin is produced in the skin as a protective barrier. The effect is not only seen in UV-sensitive Caucasians but also on low-risk individuals of dark skin complexion. The pharmacologic stimulation of MC1R could be used as a therapeutic target to darken the skin and protect it against UV damage. The use of a cAMP stimulator in addition to sunscreen might contribute to a decrease in the incidence of melanoma.

I demonstrated that the activation of MC1R induces several epidermal defenses that protect the skin against oxidative stress by upregulating antioxidant defenses. Topical application of forskolin, can directly rescue downstream targets of the MC1R. Interestingly, I was able to see that by a second application of forskolin, the skin showed an accumulation of protective melanin, and melanin stayed in the skin as long as topical forskolin treatment were continued. Taking advantage of our mouse model, I studied the activation of the MC1R as a protective target against damaging UV doses. MC1R signaling enhanced antioxidant enzymes that provide protection against oxidative stress. Nrf2 is a key transcription factor in the regulation of antioxidant enzymes. MC1R increased the expression of Nrf2 together with several regulators of glutathione activity. I found an increase in the level of antioxidant enzymes expression after six (6) hours of cAMP stimulation in human melanocytes. In addition, the rescue of MC1R by forskolin resulted in an increase of MnSOD translocation to the mitochondria and higher MnSOD activity.
I studied possible mechanisms of action for cAMP induction of MnSOD. HSP70 is a chaperone protein that was found to bind to MnSOD. I observed interactions between MnSOD and HSP70 early after treatment with forskolin. Their interaction was lost when PKA inhibitor H89 was included. Thus, PKA might have a role by phosphorylating MnSOD to be recognized and translocated to the mitochondria. Clearly, cAMP-enhanced MnSOD is PKA-dependent. Figure 4-1 summarizes the scope of chapter 2 and 3.

![Figure 4-1 Schematic representation of the research project.](image-url)
FUTURE DIRECTIONS

Studies link antioxidant defenses to many beneficial effects. Many synthetic and natural products have been reported to enhance levels of antioxidant enzymes, to prevent aging symptoms and to target UV-mediated damage. In addition, there are non-enzymatic antioxidants present in the skin. Some products that have the potential to induce antioxidant defenses in the skin include α-tocopherol, selenium, phloretin, ferulic acid, flavangenol, lipoic acid, and uric acid. I focused in the use of forskolin, a natural product that had been proved to be harmless as a topical treatment and now there is additional evidence that confirms its role in the rescue of MC1R and the induction of the protein levels of the antioxidant enzyme MnSOD.

Additional experiments are needed to determine the mechanisms by which of MC1R increases MnSOD levels in mitochondria. The proximity ligation assay (PLA) allows the study of two protein within 11nm proximity. Using this technique, one can to determine the location of the interaction between MnSOD and HSP70. I reported the inhibition of this interaction by adding H89. In addition, if the site of phosphorylation is identified, a site-directed mutagenesis assay can be performed for MnSOD abolishing of the interaction similar to the use of a PKA inhibitor.

Stimulating cAMP levels in the skin is attractive for a variety of reasons: Increasing cAMP levels in epidermal melanocytes stimulates pigment synthesis and cutaneous deposition of melanin. A proof-of-concept study using forskolin has already been shown in an animal model of the MC1R-deficient human (D'Orazio, Nobuhisa et al. 2006). The pharmacologic cAMP induction is not mutagenic (as opposed to UV). The use of spray tanning might be a safe alternative to the use of tanning beds. Sunless tanning would lessen the need for purposeful UV-seeking behavior among individuals desiring a darker skin complexion and would thus reduce the frequency of melanocyte mutations.
Increasing melanocyte cAMP levels may be a highly effective melanoma prevention strategy. Therefore, there is great interest in developing novel therapeutics to increase melanocyte cAMP levels in the skin (D’Orazio, Nobuhisa et al. 2006). There are three major approaches for increasing cAMP in melanocytes in the skin. The first mechanism of action is (1) to exploit melanocortin effects on the MC1R using α-MSH or α-MSH analogues (Haskell-Luevano, Shenderovich et al. 1995, Abdel-Malek, Ruwe et al. 2009, Abdel-Malek 2010, Abdel-Malek, Swope et al. 2014). This approach, particularly with topically-applied agents, offers the specificity of melanocyte-directed cAMP stimulation because melanocytes are thought to be the only cells in the skin that express MC1R. The limitation of MC1R-directed therapies, however, is that they would not be expected to be effective in the scenario of loss-of-function MC1R mutations and MC1R-dysfunctional individuals are the most UV-sensitive and prone to melanoma. Thus, melanocortin-based approaches allows more specificity. Other approaches rely on (2) pharmacologic induction of adenylyl cyclase activity (e.g. by forskolin), (3) inhibition of phosphodiesterase activity (e.g. by rolipram) to manipulate melanocyte cAMP levels defective of MC1R status (D’Orazio, Nobuhisa et al. 2006, Passeron, Namiki et al. 2009, Spry, Vanover et al. 2009, Khaled, Levy et al. 2010, Scott, Christian et al. 2012, Amaro-Ortiz, Vanover et al. 2013, Amaro-Ortiz, Yan et al. 2014). These agents, when applied topically, would affect cells of various types rather than being targeted only to melanocytes. Despite their lack of melanocyte specificity, however, these drugs should work even in individuals with homozygous MC1R loss-of-function and provide such persons with UV protection and melanoma prevention. The safe pathway will ensure the safety of melanocyte cAMP stimulation and to design ways of targeting agents to melanocytes in the skin to limit systemic exposure and off-target effects. Topical preparations, for example, offer direct application to the skin, however they may be challenged by ineffective transdermal penetration of the drug or systemic uptake into the
circulation from the skin. Lastly, oral or injectable routing may bypass the need for a transdermal preparation however, systemic effects would be greater. Thus, much work remains to be done to understand the usefulness and potential consequences of manipulating cAMP levels in the skin.
CONCLUSION

Despite a clear understanding of the causative role UV exposure plays in the development of the disease and widespread public health campaigns to limit time spent in the sun or artificial tanning beds, melanoma is a growing and significant public health threat. Loss-of-function polymorphisms of MC1R signaling, which result in reduced melanocyte cAMP levels, strongly correlate with fair complexion, a tendency to burn rather than tan and an increased lifetime melanoma risk. The MC1R/cAMP signaling axis not only leads to the production of UV-protective melanin, but also enhances melanocytic ability to repair UV-damaged DNA. Pharmacologic induction of MC1R pathway provides protection against sunburn. When applied to the skin, forskolin potently increases cutaneous cAMP levels and induces several UV-protective changes in melanocytes. By promoting melanocyte genomic stability, topical forskolin may prove to be a useful UV- and melanoma-preventive strategy.

My work also showed that pharmacologic activation of cAMP/MC1R signaling enhances expression of antioxidant defenses. I studied the mechanistic links between the MC1R/cAMP signaling pathway. I explored the relationships between this pro-survival and pro-differentiation melanocytic signaling pathway and the critical cellular antioxidant enzymes in the skin. I identified, for the first time a possible binding partner of MnSOD after oxidative injury, the chaperone protein HSP70. The mechanism of this interaction might be regulated by PKA, a downstream target of MC1R/cAMP signaling pathway. The use of natural products has significant potential to lessen UV-induced skin damage. This project provides a basic scientific rationale for the development of novel UV-preventive therapeutic agents based on pharmacologic activation of the MC1R/cAMP signaling axis.
APPENDIX A:

GOLDENROD EXTRACT DECREASES THE ANTI-INFLAMMATORY CAPACITY OF FAIR-SKINNED MICE AFTER UV-INDUCED ERYTHEMA IN THE SKIN.

INTRODUCTION

The neural nicotinic acetylcholine receptor alpha 7 (nAChRα7) is a four transmembrane neurotransmitter-gated ion channel (Arredondo, Nguyen et al. 2003). The expression of α7 subunit in the skin promotes keratinocyte adhesion (Arredondo, Nguyen et al. 2002) and attenuation of the pro-inflammatory responses after UV-exposure (Osborne-Hereford, Rogers et al. 2008). The role of this receptor in diseases related to the central nervous system (CNS) has been widely studied specifically in the regulation of the immune response. The CNS can modulate the immune system through the cholinergic anti-inflammatory pathway (Kurzen, Berger et al. 2004). This pathway suppresses the synthesis of cytokines utilizing the neurotransmitter acetylcholine (ACh) as an activator of nAChRα7. ACh is widely distributed and is released in organs of the reticulo-endothelial system such as the gastrointestinal tract, lungs, and kidney among others.

Epidermal keratinocytes produced ACh. The cholinergic pathway is activated by ACh and regulates blood circulation, keratinocytes differentiation (Arredondo, Nguyen et al. 2002), sweat gland formation, and immune reactions. ACh can bind to the nAChRα7 on macrophages and suppresses the release of cytokines and TNF-α. The nAChRα7 can be found in peripheral tissues. The expression nAChRα7 is increased in skin wounds (Fan, Yu et al. 2011). Other studies have focused on how nAChRα7 enhances infiltration of neutrophils in the skin (Gahring, Osborne et al. 2010).

UV radiation is able to induce an inflammatory response in the skin. High doses of UV, can lead to a painful sunburn. When the skin is injured, there is a release of cytokines and chemokine factors to increase permeability and blood flow to the skin. This leads to
swelling and redness of the area affected. If the inflammatory response is excessive, this response can cause harm to cells and surrounding tissues.

Solidago is known as goldenrod and is the state flower of Kentucky. Solidago extract, a natural product, contains many substances including flavonoids. Flavonoids are known for their permeability in vascular capillaries increasing the flow of small molecules or even whole cells to the site of inflammation (Pastore, Potapovich et al. 2009). Oral administration of flavonoids has been used to reduce allergic inflammatory disease (Tanaka 2014). In addition, clinical studies have showed positive results in skin elasticity (Delalle-Lozica 2010).

Solidago extract has been studied as a potential ligand of the nAChRα7 (Lutz, Kulshrestha et al. 2014). Solidago's structure contains an alkaloid methyllycaconitine (MLA) complex that has high affinity for the receptor. It can selectively bind to nAChRα7, leading to its activation modulating the inflammatory response at the site of injury (Lutz, Kulshrestha et al. 2014). The nAChRα7 is found in non-neuronal tissues such as the skin. It has a role in keratinocyte adhesion, cell migration, differentiation and apoptosis (Kurzen, Berger et al. 2004).

Here I studied the role of Solidago extract in skin after UV exposure. Solidago extract is a natural product that can be administered topically. I tested the capacity of solidago extract to reduce UV-induced inflammatory responses in the skin using K14-SCF Mc1r-deficient mice. For this study, the mice used were fair-skinned due to decreased MC1R signaling. Albino extension mice (Mc1r<sup>cre</sup> Tyr<sup>c2j/c2j</sup>) lacking both MC1R signaling and melanin biosynthesis were also used. I tested the capacity of short-term application of crude solidago extract to protect against UV-induced sunburn by measuring the minimal erythematous dose (MED). Moreover, I investigated gene expression in the skin, focusing on cytokines involved in the inflammatory response.
SPECIFIC AIM:

To determine the effect of Solidago against UV-induce inflammation of the skin in fair-skinned mouse model

1a) To determine the role of Solidago after a short-term topical application.

1b) To determine the MED after Solidago treatment.

1c) To examine the expression of different cytokines and its receptors in the skin.

METHODS AND MATERIALS

Protocols for murine experiments followed the guidelines for ethical conduct in the care and use of animals and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky (Protocol # 00768M2004).

MOUSE COLONY

4 to 12 week old C57BL/6 extension non-transgenic and K14-SCF transgenic extension males and females mice were used. The characteristic phenotype was blonde fur, pink skin, dark footpads and nose tip. The mice showed pheomelanotic fur, pheomelanotic epidermal skin (due to presence of interfollicular epidermal melanocytes).

REAGENTS AND MATERIALS

The following reagents were purchased commercially: Coleus Forskohlii 20% extract (Buckton Scott USA Inc, Princeton NJ); Depilatory cream Nair (Church & Dwight, Princeton, NJ); Xylazine (Anased Injection, Shanandoah, IA); Ketamine (Putney, St. Joseph, MO.); IsothesiaIsoflurane (Butler Schein, Dublin, OH); Propyl glycol (Amresco, Solon, OH) and Ethyl Ethanol (Fisher, Waltham, MA.). The following materials were purchased commercially: Chromameter CR-400 and data processor (Konica Minolta, Ramsey, NJ); Electric Shears (Oster, Atlanta, GA); NIST Radiometer/Photometer Model
IL1400A, International Light, Newburyport, MA), and Germicidal Hg Lamb UV-B (Westinghouse, Pittsburgh, PA).

**PREPARATION OF SOLIDAGO FOR TOPICAL ADMINISTRATION.**

Dr. John Littleton from the College of Pharmacy at the UKY provided the extract for Solidago. The preparation of Solidago was made by solubilizing the extract 10% weight/volume in a standard dermatologic base of 70% ethanol, 30% propylene glycol.

**SOLIDAGO (GOLDENROD) TOPICAL TREATMENT**

The skin biopsies were obtained from MC1R<sup>el/e</sup> Tyr<sup>+/+</sup> C57BL/6 animals unless otherwise stated. The mice were briefly anesthetized using an intraperitoneal injection of a standard mixture of ketamine (Putney, St. Joseph, MO.) and xylazine (Butler Schein, Dublin, OH.) (Typically 0.04 ml per 10g body weight of a mixture of 10 mg/ml ketamine and 1.0 mg/ml xylazine). The dorsal fur was removed using electric shears equipped with a 0.25mm surgical preparatory head (Fisher Scientific) followed by chemical depilation by Nair (Church and Dwight, Princeton, NJ.). After 24 hours, the mice were treated in the dorsal skin with 400uL of 10% solidago extract; vehicle control animals received 70% ethanol, and 30% propylene glycol alone. Twice daily for 3 days (6 applications) or one day applications were performed for the study. Then, 48 hours after the last topical treatment, the mice were anesthetized with ketamine and xylazine so that UV sensitivity by calculation of “Minimal Erythematosus Dose” (MED) could be determined. A UV-occlusive tape was placed on the back of the mice. The mice were placed in a UV source consisting of two Westinghouse F15T8UV-B lamps with a peak output of 313nm and a range of 280 to 370 nm. The UV dose was based on the UV transmission rate and it was measured by a UV Photometer. The UV exposure time was calculated for each desired dose based on the UV output of the source. The mice were monitored for 24 to 48 hours for discreet areas of erythema (redness) or edema (swelling) corresponding to the anatomic sites.
exposed to the specific dose of UV irradiation. The skin findings were documented photographically.

mRNA ISOLATION FROM TISSUE SAMPLES

The skin biopsies were taken at desired time-points. Frozen skin tissues were triturated using liquid nitrogen with a mortal and pedestal. The skin was homogenized with Trizol® reagent following manufacturer protocol. The mRNA was clean-up using the RNeasy kit (Qiagen, Valencia, CA.) following the manufacturer protocol. The pure mRNA was quantified, normalized and converted to cDNA using the iScript cDNA kit (Qiagen, Valencia, CA.).

qPCR

The cells were plated in 35mm dishes and treated for cAMP stimulation. Treatments included 10µM forskolin or 0.1% vehicle control and untreated cells as the control samples. The cells were dissociated by treatment with 0.25% trypsin/EDTA at 37°C for 5 min. The cells were harvested, centrifuged and RNA was isolated using the RNAeasy kit (Qiagen, Valencia, CA.). RNA was converted to cDNA using the iScript cDNA kit (Qiagen, Valencia, CA.). The cDNA was used to perform quantitative PCR assay by the CF-96 Biorad qPCR with the Actin β as a reference gene included for each reaction. The levels of expression of genes in stimulated cells were compared with the untreated and control groups.

STATISTICAL ANALYSIS

The data was analyzed between cohorts of replicates samples (n = 3) by one-way ANOVA using the Bonferroni post-test (Graph Pad PRISM software). p values <0.01 were considered statistically significant.
RESULTS

**Solidago decreases MED in Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> mice after UV-exposure.**

I studied the effects of topical treatment of solidago (goldenrod) extract on preventing UV-induced skin inflammation using the *K14-SCF Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>* mouse model (Fig 5-1). I tested the role of Solidago in the skin by measuring minimal erythematous dose, MED. Topical administration of Solidago extract had no effect on darkening of the skin (Figure 5-2C, D). After applying solidago twice daily for 3 days (10% Solidago per dose), the average MED for *K14-SCF extension* (Mc1<sup>e/e</sup> Tyr<sup>+/+</sup>) mice was significantly higher with 10.0 ± 0.0 kJ/m<sup>2</sup> compared to 4.0 ± 0.0 kJ/m<sup>2</sup> for the vehicle control treated group (Fig. 5-2 C). The average MED in *K14-SCF albino extension* (Mc1<sup>e/e</sup> Tyr<sup>c2j/c2j</sup>) mice treated with solidago and vehicle were 3.3 ± 1.2 kJ/m<sup>2</sup> and 0.8 ± 0.4 kJ/m<sup>2</sup>, respectively (Fig. 5-2 D). There was no significant difference in the erythema of the skin for albino extension mice treated with solidago. Here I concluded that Solidago decreased UV-induced inflammation in fair-skinned mice.

**One topical treatment of Solidago in Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> mice after UV-exposure did not decrease MED.**

I performed another experiment with only one application of 10% solidago followed by UV-exposure in *K14-SCF extension* (Mc1<sup>e/e</sup> Tyr<sup>+/+</sup>) mice (Figure 5-3). Two groups of mice were pretreated with solidago for 3 or 6 hours before UV exposure. The average MED for the 3 hours group was 2.0 ± 0.0 kJ/m<sup>2</sup> for both solidago and vehicle control. However, for the mice irradiated 6 hours after solidago treatment, the MED was 4.0 ± 0.0 kJ/m<sup>2</sup> compared to 2.0 ± 0.0 kJ/m<sup>2</sup> for vehicle control (Figure 5-3B). Although the MED was decreased, these results were not significant. There was no significant difference in both groups. I concluded that one application of 10% solidago was not enough to promote an anti-inflammatory response.
SOLIDAGO DECREASE THE INFLAMMATORY RESPONSE AT LOWER DOSES OF UVB.

I performed a gene array for the expression of several cytokines and its receptors that are involved in the inflammatory response. Solidago was applied twice daily for 3 days (10% Solidago per dose), to measure MED for K14-SCF albino extension. Doses of 2kJ/m² and 6 kJ/m² were used for gene analysis. These doses of UV elicit a low and high inflammatory response in the mouse skin. The MED of K14-SCF albino extension (Mc1r e/e Tyr c2j/c2j) was measured 48 hours after UV-exposure. The 48 hour time-point was selected to analyze 60 genes that include inflammatory cytokines and its receptor. Out of the genes tested, there were 24 chemokines, 7 chemokine receptors, 7 interleukins, 9 interleukins receptors and others 13 cytokines and its receptors. Of these, there was a decrease in the expression of the majority of pro-inflammatory genes after Solidago treatment compared to vehicle control and a 2 kJ/m² dose. There was a decrease in the expression of several cytokines (Ccl1, Cx3cl1, IL15 family among other genes relative to the expression of Actb) (Table 5-1), but there were significant increases in the expression of IL1r1, and Tnfsf13. I noted an increase in the gene expression of several genes after a 6 kJ/m² exposure. There was an even higher increase in the expression of IL1r1 and Tnfsf13 were increased by 2 and 6 fold respectively, relative to vehicle. Ccl11 and Cxcl15 had a 2 and 7 fold increase after Solidago treatment, respectively (Table 5-1). Thus, I concluded that topically-applied Solidago decreased the inflammatory response at low doses of UV-exposure.

SOLIDAGO DECREASES Tnf-α SIGNALING IN Mc1R e/e TYR+/+ MICE AFTER UV-EXPOSURE.

Previous studies showed the expression of three specific genes as key targets for the inflammatory response (Osborne-Hereford, Rogers et al. 2008). Therefore, I tested the expression of Tnf-α, IL1β and IL6 (Figure 5-4) in K14-SCF albino extension. The skin biopsies were taken after irradiating the skin with 2 or 6 kJ/m² of UV. For a low dose of 2
kJ/m², there was a decrease in the gene expression of Tnf-α and IL1β after treatment of 10% solidago compared to vehicle control. But, there was an increase of 4 fold for the gene expression of IL6 after solidago.

Interestingly, for the 6kJ/m², there was an increase of 4 fold for IL1β comparing vehicle with solidago treatment. The gene expression of IL6 increased 9 fold after solidago treatment. However, Tnf-α gene expression was decreased 2 fold after solidago treatment. The inhibition of the inflammatory response mediated by solidago may be dependent of the expression of Tnf-α.
A.

<table>
<thead>
<tr>
<th>Melanocortin 1 receptor</th>
<th>K14-Scf Transgene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mc1r&lt;sup&gt;e/e&lt;/sup&gt;</td>
<td>Non-transgenic</td>
</tr>
<tr>
<td>Ty&lt;sup&gt;r&lt;sup&gt;+/+&lt;/sup&gt;&lt;/sup&gt;</td>
<td>K14-Scf</td>
</tr>
<tr>
<td>Mc1r&lt;sup&gt;e/e&lt;/sup&gt;</td>
<td>Non-transgenic</td>
</tr>
<tr>
<td>Ty&lt;sup&gt;r&lt;sup&gt;−/−&lt;/sup&gt;&lt;/sup&gt;</td>
<td>K14-Scf</td>
</tr>
</tbody>
</table>

Face/head

Left ear (close-up)

Figure 5-1. Topical treatment of Solidago in fair-skinned extension and albino extension mice. (Mc1r<sup>e/e</sup>) mice photographs of C57BL/6 animals were used in this study. Animals were genetically matched except at the melanocortin 1 receptor (Mc1r) and Tyrosinase (Tyr) loci. Note that pigmentation is pheomelanotic (blond) when Tyr is functional but amelanotic (albino) when Tyr is defective, as is the case with the albino extension (Mc1r<sup>e/e</sup> Tyr<sup>−/−</sup>) mutant. (B) Epidermal pigmentation depends on retention of interfollicular epidermal melanocytes in the skin by the K14-SCF transgene, and the skin darkening can easily be seen in the ears.
Figure 5-2. Solidago protected against UV-mediated inflammation as determined by minimal erythematous dose (MED) testing.

(A, C) Position of UV occlusive tape and UVB doses of animals treated twice daily for 3 days with 10% solidago and vehicle control (70% ethanol 30% propyl glycol). Dorsal skin was exposed to various doses of UVB by using UV-occlusive tape with punched-out 1 cm² circular apertures, and varying exposure times to yield the appropriate dose. (B, D) Mc1re/e Tyr+/+ and Mc1re/e Tyr<sup>c2j/c2j</sup> were irradiated after the completion of the last treatment (6 applications). After irradiation, circles of exposed skin were labeled with a pen in some experiments. MED’s, defined by erythema and/or edema in the entire circle of exposed skin to a particular dose, were determined 48 hours after exposure. The MED ± SD results are reported as kJ/m² UVB, p ≤ 0.001.
Figure 5-3. Solidago protected against UV-mediated inflammation as determined by minimal erythematosus dose (MED) testing.

(A) Position of UV occlusive tape and UVB doses of animals once one day with 10% solidago and vehicle control (70% ethanol 30% propyl glycol). Dorsal skin was exposed to various doses of UVB by using UV-occlusive tape with punched-out 1 cm² circular apertures, and varying exposure times to yield the appropriate dose. (B) Mc1r<sup>ty</sup> <sup>ts</sup>/<sup>t</sup> Tyr<sup>+/+</sup> mice were treated with solidago 3 and 6 hours prior to UV exposure. After irradiation, circles of exposed skin were labeled with a pen in some experiments. MED's, defined by erythema and/or edema in the entire circle of exposed skin to a particular dose, were determined 48 hours after exposure. The MED ± SD results are reported as kJ/m² UVB, * p ≤ 0.001.

Experiment performed in collaboration with Kaia Hampton.
Table 5-1. Cytokines gene array, the expression of different genes after solidago treatment.

Mc1r<sup>+/e</sup> Tyr<sup>-2/+c2</sup> albino extension were treated with 10%<sub>w/v</sub> Solidago and vehicle control (70% ETOH, 30% PG) twice daily for 3 days. Skin biopsies were taken after 48 hours of exposure to 2 or 6 kilojoules of UVB. mRNA was isolated to be analyzed by qPCR using RT<sup>2</sup> Profiler PCR Array for inflammatory cytokines and receptors (Qiagen, Valencia, CA.) with primers specific for mouse mRNA. The gene amplification was normalized to Actin β and the relative amplification levels at both UVB doses were compared to vehicle control.

Experiment performed in collaboration with Kaia Hampton.
**Figure 5-4. Solidago inhibited Tnf-α expression after UV-induced inflammation.**

Mc1r<sup>e/e</sup> Tyr<sup>c2j/c2j</sup> albino extension were treated with 10% w/v Solidago and vehicle control (70% ETOH, 30% PG) twice daily for 3 days. Skin biopsies were taken after 48 hours of exposure to 2 or 6 kJ/m<sup>2</sup> of UVB. mRNA was isolated to be analyzed by qPCR using RT<sup>2</sup> Profiler PCR Array for inflammatory cytokines and receptors (Qiagen, Valencia, CA.) with primers specific for mouse mRNA. The gene amplification was normalized to Actin β (Actb) and the relative amplification levels at both UVB doses were compared to vehicle control.

Experiment performed in collaboration with Kaia Hampton.
DISCUSSION

The anti-inflammatory response of solidago is mediated by its binding to nAChRα7. This receptor has been found to be expressed in the skin (Zia, Ndoye et al. 2000, Arredondo, Nguyen et al. 2002, Bencherif, Lippiello et al. 2011, Fan, Yu et al. 2011). I hypothesized that the solidago extract would protect against UV-inflammation in K14-SCF Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> and Mc1r<sup>e/e</sup> Tyr<sup>c2j/c2j</sup> mice. This is the first study using a topical formulation of solidago. I confirmed my hypothesis in C57BL/6 extension (Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup>) mice. I was not able to observe darkening of the skin after 6 applications of the solidago extract on the back of the mice in contrast to forskolin, which induced darkening of the skin after two topical applications. This was not a surprise since the effects of solidago are known to affect inflammatory response rather than pigmentation. However, there was a protective effect against erythema with a 4.0 kJ/m<sup>2</sup> compared to 10.0 kJ/m<sup>2</sup> in Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> fair-skinned mice. I tested the drug in Mc1r<sup>e/e</sup> Tyr<sup>c2j/c2j</sup> albino extension mice but the increase in MED was not significant. Perhaps, the presence of pheomelanin may have a protective effect against UV-induced inflammation in the skin. To address these differences, further experiments are required with more mice or a higher percentage of solidago extract in the skin. The UV exposure of the Mc1r<sup>e/e</sup> Tyr<sup>c2j/c2j</sup> albino extension was lower (0.5 to 6.0 kJ/m<sup>2</sup>) from Mc1r<sup>e/e</sup> Tyr<sup>+/+</sup> extension (1.0 to 10 kJ/m<sup>2</sup>) because amelanotic albino show more UV sensitivity. I was not able to test higher doses of UV, for the reason that without the darkening of the skin, higher doses of UV would harm the mice and cause excessive sunburn.

The use of solidago in both extension and albino extension mice, promoted decreases in the inflammatory response. The solidago extract has shown no physiological effect after treatment in mice (Bucciarelli, Minetti et al. 2010). Application of solidago for only one day show no significant effect protecting against UV-inflammation of the skin.
Other studies using chronic treatment (more than 3 days) of topical solidago are needed to study its effect inhibiting the inflammatory response.

Based on the results above, the mechanism of solidago-induced protection is melanin-independent. Skin samples taken from Mc1r<sup>e/e</sup> Tyr<sup>c2j/c2j</sup> albino extension mice were tested for the expression of several genes involved in the inflammatory response. The gene expression of the majority of cytokines and receptors was decreased at low UV but not at 6 kJ/m<sup>2</sup> suggesting a protective threshold. However, the expression of IL1r1 and Tnfsf13 was increased in both doses. These cytokines have been used as a target to test inhibition of the inflammatory response (Li, Pappas et al. 2013, Garcia-Perez, Allaey et al. 2014, Tsai, Tung et al. 2015). The use of flavonoids such as solidago might yield protective effects after UV exposure perhaps more effective at lower doses of UV.

The inflammatory response consists of many cytokines receptors. An example of pro-inflammatory cytokines include IL23, IL17, IL6, IL8, IL10, and Tnf-α among others. IL6 is expressed in severe skin sunburn (Norval 2001, Norval 2011). IL6 promotes the release of Tnf-α, IL12, IL1 and other cytokines promoting inflammation. IL6 showed a high expression when tested in the skin treated with 6 kJ/m<sup>2</sup> of UV radiation on albino extension mice confirming its role in skin sunburn. Tnf-α is a pro-inflammatory cytokine and solidago decreased it at both low and high doses of UV. On the other hand, there are anti-inflammatory cytokines like IL13, IL11, and IL4. IL4 and IL13 known to promote tissue repair together with the production of specific antibodies (Voehringer 2013), therefore some beneficial effects of inflammation may be lost by Solidago treatment.

I also noted decreases in the expression of Tnf-α and IL1β after solidago treatment at lower doses of UVB. The decrease remained after increasing the dose of UVB to 6 kJ/m<sup>2</sup> for Tnf-α. However, IL1β and IL6 showed an increase in the expression after an exposure of 6 kJ/m<sup>2</sup>. This dose of UVB showed an increase in skin redness of the mice.
The protective effect of solidago at higher doses of UVB might be linked to the regulation of Tnf-α. Remarkably, Tnf-α is known to regulate dendritic and macrophages density in the immune response (Marble, Gordon et al. 2007) and IL6 can inhibit endotoxin-induced Tnf-α signaling (Starkie, Ostrowski et al. 2003). Additional studies are required to determine if solidago can directly regulate IL6 as an anti-inflammatory cytokine.

The use of solidago for the prevention of inflammation after UVB exposure would potentially be of benefit to individuals with UV sensitivity. It is important to consider that the solidago extract contains many other components that might have a role in the skin response. Therefore, further studies are needed to understand the absorption of this drug in the skin and to clarify which components are inflammation regulators. Better absorption might allow more significant results at higher doses of UV. It would be ideal to observe an anti-inflammatory effect using less than 6 application of solidago (in a matter of hours).

I hypothesized that solidago acted as an agonist to the nAChrα7 to decrease cytokine production. Although nAChRα7 has been implicated in wound healing (Fan, Yu et al. 2011) and skin infection (Gahring, Osborne et al. 2010), its pharmacologic activation in the absence ACh or parasympathetic innervation is a novel mechanism. The nAChRα7 being expressed in non-neuronal locations regulates early local inflammatory responses in the skin. This suggests that the effect of this receptor might be beneficial even without UV-exposure. In support of our hypothesis, it is clear that several pro-inflammatory cytokines were down-regulated at the gene level after topical application of solidago activates nAChRα7 response and inhibits the inflammatory response.
APPENDIX B:

PERMISSION LETTER TO RE-USE FIGURES

1 Alewife Center, Suite 200
Cambridge, MA 02140
tel: 617.945.9051
fax: 866.381.2236

Hi Alexandra,

You have our permission to use part or all of your JoVE article "Amaro-Ortiz, A., Vanover, J. C., Scott, T. L., D'Orazio, J. A. Pharmacologic Induction of Epidermal Melanin and Protection against Sunburn in a Humanized Mouse Model. J. Vis. Exp. (79), e50670, doi:10.3791/50670 (2013)." in your dissertation as requested.

Please be sure to cite the JoVE article in the figure legends and general references as applicable.

Please consider this letter as approval.

Best,

Michelle

Michelle E. Kinahan, Ph.D.
Deputy Director of Editorial - Review
JoVE
1 Alewife Center, Suite 200, Cambridge, MA 02140
tel: 617-674-1888
APPENDIX C:

LIST OF ABBREVIATIONS

6-4 PP  
8-oxoG  
A  
ACTB  
ADIPOQ  
ADP  
AGTR1  
AIMP1  
AKT1  
APEX1  
APOA1  
APP  
ARE  
ATF2  
ATP  
B2M  
BCL2  
BMP2  
C  
cAMP  
CASP3  
CAT  
CCL1  
CCL11  
CCL12  
CCL17  
CCL19  
CCL2  
CCL20  
CCL22  
CCL24  
CCL3  
CCL4  
CCL5  
CCL6  
CCL7  
CCL8  
CCL9  
CCR1  
CCR10  
CCR2  
CCR3  
CCR4  
CCR5

6-4 photoproduct
8-oxoguanine
adenine
Actin, beta
adiponectin, C1Q and collagen domain containing
Adenosine diphosphate
angiotensin II receptor, type 1
Aimp1 Aminoacyl tRNA synthetase complex-interacting multifunctional protein 1
v-akt murine thymoma viral oncogene homolog 1
nuclease (multifunctional DNA repair enzyme) 1
apolipoprotein A-I
amyloid beta (A4) precursor protein
antioxidant response element
activating transcription factor 2
adenosine triphosphate
Adenosine triphosphate
B2m Beta-2 microglobulin
B-cell CLL/lymphoma 2
Bmp2 Bone morphogenetic protein 2
cytosine
3’-5’-cyclic adenosine monophosphate
caspase 3, apoptosis-related cysteine peptidase
catalase
Chemokine (C-C motif) ligand 1
Chemokine (C-C motif) ligand 11
Chemokine (C-C motif) ligand 12
Chemokine (C-C motif) ligand 17
Chemokine (C-C motif) ligand 19
Chemokine (C-C motif) ligand 2
Chemokine (C-C motif) ligand 20
Chemokine (C-C motif) ligand 22
Chemokine (C-C motif) ligand 24
Chemokine (C-C motif) ligand 3
Chemokine (C-C motif) ligand 4
Chemokine (C-C motif) ligand 5
Chemokine (C-C motif) ligand 6
Chemokine (C-C motif) ligand 7
Chemokine (C-C motif) ligand 8
Chemokine (C-C motif) ligand 9
Chemokine (C-C motif) receptor 1
Chemokine (C-C motif) receptor 10
Chemokine (C-C motif) receptor 2
Chemokine (C-C motif) receptor 3
Chemokine (C-C motif) receptor 4
Chemokine (C-C motif) receptor 5
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCR6</td>
<td>Chemokine (C-C motif) receptor 6</td>
</tr>
<tr>
<td>CCR8</td>
<td>Chemokine (C-C motif) receptor 8</td>
</tr>
<tr>
<td>CD36</td>
<td>molecule (thrombospondin receptor)</td>
</tr>
<tr>
<td>CD40LG</td>
<td>CD40 ligand</td>
</tr>
<tr>
<td>CLU</td>
<td>clusterin</td>
</tr>
<tr>
<td>CPD</td>
<td>cyclobutane pyrimidine dimer</td>
</tr>
<tr>
<td>CREB</td>
<td>cAMP response element binding</td>
</tr>
<tr>
<td>CSF1</td>
<td>Colony stimulating factor 1 (macrophage)</td>
</tr>
<tr>
<td>CSF2</td>
<td>Colony stimulating factor 2 (granulocyte-macrophage)</td>
</tr>
<tr>
<td>CSF3</td>
<td>Colony stimulating factor 3 (granulocyte)</td>
</tr>
<tr>
<td>Cu/ZnSOD</td>
<td>copper/zinc superoxide dismutase</td>
</tr>
<tr>
<td>CX3CL1</td>
<td>Chemokine (C-X3-C motif) ligand 1</td>
</tr>
<tr>
<td>CXC12</td>
<td>Chemokine (C-X-C motif) ligand 12</td>
</tr>
<tr>
<td>CXCL1</td>
<td>Chemokine (C-X-C motif) ligand 1</td>
</tr>
<tr>
<td>CXCL10</td>
<td>Chemokine (C-X-C motif) ligand 10</td>
</tr>
<tr>
<td>CXCL11</td>
<td>Chemokine (C-X-C motif) ligand 11</td>
</tr>
<tr>
<td>CXCL13</td>
<td>Chemokine (C-X-C motif) ligand 13</td>
</tr>
<tr>
<td>CXCL15</td>
<td>Chemokine (C-X-C motif) ligand 15</td>
</tr>
<tr>
<td>CXCL5</td>
<td>Chemokine (C-X-C motif) ligand 5</td>
</tr>
<tr>
<td>CXCL9</td>
<td>Chemokine (C-X-C motif) ligand 9</td>
</tr>
<tr>
<td>CXCR2</td>
<td>Chemokine (C-X-C motif) receptor 2</td>
</tr>
<tr>
<td>CXCR3</td>
<td>Chemokine (C-X-C motif) receptor 3</td>
</tr>
<tr>
<td>CXCR5</td>
<td>Chemokine (C-X-C motif) receptor 5</td>
</tr>
<tr>
<td>CYBA</td>
<td>cytochrome b-245, alpha polypeptide</td>
</tr>
<tr>
<td>CYCS</td>
<td>cytochrome c, somatic</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>cytochrome P450, family 2, subfamily E, polypeptide 1</td>
</tr>
<tr>
<td>DCT</td>
<td>dopachrome tautomerase</td>
</tr>
<tr>
<td>DDIT3</td>
<td>DNA-damage-inducible transcript 3</td>
</tr>
<tr>
<td>DHCR24</td>
<td>24-dehydrocholesterol reductase</td>
</tr>
<tr>
<td>DHICA</td>
<td>5,6-dihydroxyindole-carboxylic acid</td>
</tr>
<tr>
<td>ECSOD</td>
<td>extracellular superoxide dismutase</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>F3</td>
<td>coagulation factor III (thromboplastin, tissue factor)</td>
</tr>
<tr>
<td>FASL</td>
<td>Fas ligand (TNF superfamily, member 6)</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal Bovine Serum</td>
</tr>
<tr>
<td>FOXO1</td>
<td>forkhead box O1</td>
</tr>
<tr>
<td>G6PD</td>
<td>glucose-6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GPX1</td>
<td>glutathione peroxidase 1</td>
</tr>
<tr>
<td>GPX3</td>
<td>glutathione peroxidase 3 (plasma)</td>
</tr>
<tr>
<td>GPX4</td>
<td>glutathione peroxidase 4 (phospholipid hydroperoxidase)</td>
</tr>
<tr>
<td>GSH</td>
<td>glutathione</td>
</tr>
<tr>
<td>GSR</td>
<td>glutathione reductase</td>
</tr>
<tr>
<td>GSTP1</td>
<td>glutathione S-transferase pi 1</td>
</tr>
<tr>
<td>GUSB</td>
<td>Glucuronidase, beta</td>
</tr>
</tbody>
</table>
H₂O₂     Hydrogen Peroxide
HIF1A     hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
HMOX1     heme oxygenase (decycling) 1
HP         haptoglobin
HPRT1     hypoxanthine phosphoribosyltransferase 1
HSP90A1    Heat shock protein 90 alpha (cytosolic), class B member 1
HSPD1      heat shock 60kDa protein 1 (chaperonin)
IFNG       Interferon gamma
IL10RA     Interleukin 10 receptor, alpha
IL10RB     Interleukin 10 receptor, beta
IL11       Interleukin 11
IL13       Interleukin 13
IL15       Interleukin 15
IL16       Interleukin 16
IL17A      Interleukin 17A
IL17B      Interleukin 17B
IL17F      Interleukin 17F
IL1A       Interleukin 1 alpha
IL1B       Interleukin 1 beta
IL1B       Interleukin 1, beta
IL1R1      Interleukin 1 receptor, type I
IL1RN      Interleukin 1 receptor antagonist
IL21       Interleukin 21
IL27       Interleukin 27
IL2RB      Interleukin 2 receptor, beta chain
IL2RG      Interleukin 2 receptor, gamma chain
IL3        Interleukin 3
IL33       Interleukin 33
IL4        Interleukin 4
IL5        Interleukin 5
IL5RA      Interleukin 5 receptor, alpha
IL6        Interleukin 6 (interferon, beta 2)
IL6RA      Interleukin 6 receptor, alpha
IL6ST      Interleukin 6 signal transducer
IL7        Interleukin 7
INS        insulin
IP         Intraperitoneal
JAK2       Janus kinase 2
JUN        proto-oncogene
kDA        kilodalton
LCN2       lipocalin 2
LDHA       lactate dehydrogenase A
LTA        Lymphotoxin A
LTB        Lymphotoxin B
MAP3K5     mitogen-activated protein kinase kinase kinase 5
MAPK1      mitogen-activated protein kinase 1
MAPK8      mitogen-activated protein kinase 8
MAPK9      mitogen-activated protein kinase 9
MC1R       melanocortin 1 receptor
α-MSH      alpha melanocyte stimulating hormone
MDM2    p53 binding protein homolog (mouse)
MED      minimal erythema dose
MGDC    Mouse Genomic DNA Contamination
MIF     Macrophage migration inhibitory factor
MIF     macrophage migration inhibitory factor (glycosylation-inhibiting factor)
Mitf    microphthalmia transcription factor
MnSOD   manganese superoxide dismutase
MPO     myeloperoxidase
MSRA    methionine sulfoxide reductase A
mtDNA   mitochondrial DNA
NAMPT   Nicotinamide phosphoribosyltransferase
NFE2L2   nuclear factor (erythroid-derived 2)-like 2
NFKB1   nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
NMSC    non-melanoma skin cancer
NOS1    nitric oxide synthase 1 (neuronal)
NOX1    NADPH oxidase 1
NQO1    NAD(P)H dehydrogenase, quinone 1
Nrf2    Nuclear factor-like 2
OGG1    8-oxoguanine DNA glycosylase
OLR1    oxidized low density lipoprotein (lectin-like) receptor 1
OSM     Oncostatin M
PARK7   Parkinson disease (autosomal recessive, early onset) 7
PBS     Phosphate Buffer Saline
PF4     Platelet factor 4
PKA     protein kinase A
POMC    proopiomelanocortin
PON2    paraoxonase 2
PRDX1   peroxiredoxin 1
PRDX2   peroxiredoxin 2
PRDX3   peroxiredoxin 3
PRDX4   peroxiredoxin 4
PRDX5   peroxiredoxin 5
PRDX6   peroxiredoxin 6
PRKAA2  protein kinase, AMP-activated, alpha 2 catalytic subunit
PRKCA   protein kinase C, alpha
PRKCB   protein kinase C, beta
PRKCD   protein kinase C, delta
PRK CZ  protein kinase C, zeta
PRODH   proline dehydrogenase (oxidase) 1
PTGS2   prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
RELA    v-rel reticuloendotheliosis viral oncogene homolog A (avian)
RHC     red hair color phenotype
RNS     reactive nitrogen species
ROS     reactive oxygen species
ROS1    c-ros oncogene 1, receptor tyrosine kinase
SCF     stem cell factor
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SERPINE1</td>
<td>serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1</td>
</tr>
<tr>
<td>SHC1</td>
<td>SHC (Src homology 2 domain containing) transforming protein 1</td>
</tr>
<tr>
<td>SIRT1</td>
<td>sirtuin 1</td>
</tr>
<tr>
<td>SNCA</td>
<td>synuclein, alpha (non A4 component of amyloid precursor)</td>
</tr>
<tr>
<td>SOD</td>
<td>superoxide dismutase</td>
</tr>
<tr>
<td>SOD1</td>
<td>superoxide dismutase 1, soluble</td>
</tr>
<tr>
<td>SOD2</td>
<td>superoxide dismutase 2, mitochondrial</td>
</tr>
<tr>
<td>SOD3</td>
<td>superoxide dismutase 3, extracellular</td>
</tr>
<tr>
<td>SPP1</td>
<td>Spp1 Secreted phosphoprotein 1</td>
</tr>
<tr>
<td>SRC</td>
<td>v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)</td>
</tr>
<tr>
<td>STAT1</td>
<td>signal transducer and activator of transcription 1, 91kDa</td>
</tr>
<tr>
<td>TBS-T</td>
<td>tris buffered saline – tween 20</td>
</tr>
<tr>
<td>TLR4</td>
<td>toll-like receptor 4</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>TNFRSF11B</td>
<td>Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)</td>
</tr>
<tr>
<td>TNFSF10</td>
<td>Tumor necrosis factor (ligand) superfamily, member 10</td>
</tr>
<tr>
<td>TNFSF11</td>
<td>Tumor necrosis factor (ligand) superfamily, member 11</td>
</tr>
<tr>
<td>TNFSF13</td>
<td>Tumor necrosis factor (ligand) superfamily, member 13</td>
</tr>
<tr>
<td>TNFSF13B</td>
<td>Tumor necrosis factor (ligand) superfamily, member 13b</td>
</tr>
<tr>
<td>TNFSF4</td>
<td>Tumor necrosis factor (ligand) superfamily, member 4</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein p53</td>
</tr>
<tr>
<td>TXNIP</td>
<td>thioredoxin interacting protein</td>
</tr>
<tr>
<td>TXNRD1</td>
<td>thioredoxin reductase 1</td>
</tr>
<tr>
<td>Tyr</td>
<td>tyrosinase</td>
</tr>
<tr>
<td>Trp1</td>
<td>tyrosine related protein 1</td>
</tr>
<tr>
<td>Trp2</td>
<td>tyrosine related protein 2</td>
</tr>
<tr>
<td>UCP1</td>
<td>uncoupling protein 1</td>
</tr>
<tr>
<td>UCP2</td>
<td>uncoupling protein 2 (mitochondrial, proton carrier)</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>UVA</td>
<td>ultraviolet A</td>
</tr>
<tr>
<td>UVB</td>
<td>ultraviolet B</td>
</tr>
<tr>
<td>UVC</td>
<td>ultraviolet C</td>
</tr>
<tr>
<td>VDAC</td>
<td>voltage-dependent anion channel</td>
</tr>
<tr>
<td>VEGFA</td>
<td>Vascular endothelial growth factor A</td>
</tr>
<tr>
<td>XO</td>
<td>xanthine oxidase</td>
</tr>
</tbody>
</table>
° (1994). "[A consensus statement for the prevention of melanoma. Changes in sunbathing habits are most important. Tanning salons are too popular among young people]." Lakartidningen 91(50): 4778-4782.


Alexandra Amaro-Ortiz

Education

08/10-present    Ph.D., Toxicology, University of Kentucky, Lexington, KY
08/09-06/10    Post B.S., Pharmaceutical Science, University of Puerto Rico, Medical Science Campus, San Juan, PR
08/05-05/09    B.S., Chemistry, University of Puerto Rico Rio Piedras Campus, San Juan, PR

Professional Experiences

08/10-present Graduate Research Assistant, University of Kentucky, Lexington KY
08/09-07/10    Graduate Research Assistant, University of Puerto Rico, San Juan, PR
06/08-08/08    Undergraduate Research Assistant, University of Arizona, Tucson, AZ
08/07-05/08    Undergraduate Research Assistant, University of Puerto Rico, San Juan, PR
06/07-08/07    Undergraduate Research Assistant, University of Kentucky, Lexington KY

Laboratory Rotation trainees

10/12-4/14    Betty Yan, Medical student, Professional Student Mentored Research Fellowship, University of Kentucky (18 months)
10/12-4/14    Claci Ayers, Undergraduate Student, Honors Program, Univ. KY. (18 months)
10/13-12/13    Kaia Hampton, IBS Graduate Student, University of Kentucky (8 weeks)
6/12-8/12     Brenda Patel, Undergraduate Student from Georgetown College. Summer research for undergraduate students as part of the HHMI-funded Georgetown College Program to Accelerate Learning in the Sciences (GCPALS). (10 weeks)
1/12-3/12     Jared Vasquez, IBS Graduate Student, University of Kentucky (8 weeks)
10/11-12/11    Karine Oden, IBS Graduate Student, University of Kentucky (8 weeks)

Awards and/or Scholarships

08/10-03/12    Lyman T. Johnson Fellowship, $7,500 per year plus ½ tuition. Remaining support provided by Graduate Center for Toxicology departmental funds.
06/08-05/09    SMART Scholarship for Undergraduate Studies 2008-2009 -For undergraduate students to complete the B.S. degree.
06/05-05/09    Robert C. Bird Scholarship for Undergraduate Studies 2005-2009 -For undergraduate students to complete the B.S. degree.
06/05-07/06    The Ronald McDonald Foundation Scholarship- For first year undergraduate students enroll in a college degree.
12/06    Travel Award to Puebla, Mexico – As a member of P.E.C.E.S., Inc. To encourage primary and secondary school students to pursue a career.
Scientific publications

Original Article


Book Chapter


Review Article


Abstracts and Lectures

8/14 Amaro-Ortiz, A., Ayer, C., Yan, B. and J.A. D’Orazio. Pharmacologic induction of the melanocortin 1 receptor (MC1R) pathway provides protection against sunburn and enhances expression of MnSOD in the skin. 2014 Natural Product Consortium Symposium, Lexington, KY


5/14 Amaro-Ortiz, A., Ayer, C., Yan, B. and J.A. D’Orazio. The melanocortin 1 receptor (MC1R) pathway enhances expression of MnSOD and protects against ROS-induced oxidative stress in human melanocytes. 16th Annual Midwest DNA Repair Symposium, Detroit, MI.

11/13 Amaro-Ortiz, A. Melanocortin 1 receptor (Mc1r) signaling mediates protection against skin cancer.
10/13 Amaro-Ortiz, A., S.G. Jarrett, C.W. Allen and J.A. D’Orazio. Melanocortin 1 receptor (Mc1r) signaling mediates up-regulation of anti-oxidant enzymes. *2nd Annual Appalachian Regional Cell Conference, Charleston, W.V.*


5/13 Amaro-Ortiz, A., S.G. Jarrett, C.W. Allen and J.A. D’Orazio. Melanocortin 1 receptor (Mc1r) signaling mediates up-regulation of anti-oxidant enzymes and protects against UV-induced mitochondrial damage. *15th Annual Midwest DNA Repair Symposium, Lexington, KY. (Poster Award, Second Place)*


5/12 Amaro-Ortiz, A., P. Murapa and JA D’Orazio. “Melanocytic anti-oxidant enzymes are regulated by melanocortin 1 receptor (Mc1r) signaling”. *14th Annual Midwest DNA Repair Symposium, Cincinnati, OH.*

5/12 Amaro-Ortiz, A., P. Murapa and JA D’Orazio. “Melanocytic anti-oxidant enzymes are regulated by melanocortin 1 receptor (Mc1r) signaling”. *2012 Markey Cancer Center Research Day, Lexington, KY.*

03/09 Puerto Rico Interdisciplinary Scientist Meeting (PRISM) and 5rd Junior Technical Meeting. *San Juan, PR*

11/08 Annual Biomedical Research Conference for Minority Students. *Orlando, FL*

03/08 Puerto Rico Interdisciplinary Scientist Meeting (PRISM) and 4rd Junior Technical Meeting. *Arecibo, PR*